[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"89 NORTH\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":367},{"warningLetters":4,"total":366},[5,31,52,74,96,114,137,154,170,191,214,233,251,270,289,304,324,346],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2566,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-07-19T13:20:00Z\">07\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-24T04:00:00Z\">06\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth30-llc-633737-06242022\">North30 LLC\u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Elaine (Xaio) Song\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North30 LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15552 Lake Hills Blvd # F-5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bellevue\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98007-5928\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 24, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 633737\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Song:\u003C\u002Fp>\n\n\u003Cp>On March 14 through April 8, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of North30 LLC, located at 15552 Lake Hills Blvd # F-5 Bellevue, WA 98007-5928. We also conducted an inspection April 16 through May 7, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of this significant violation, your firm is not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on April 8, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violation of the FSVP regulation is as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following food products:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Passion Fruit Sauce, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Taro, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Mesona Extract, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We acknowledge that during the most recent inspection, you told our investigator that your firm is expecting to transition to a model where the foods are imported by your franchise office in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and then your firm would receive the foods after importation. As of the date of this letter, we have not received any information regarding your FSVPs or planned corrective actions. According to our records, your firm continued to import food following the end of the inspection on April 8, 2022.\u003C\u002Fp>\n\n\u003Cp>The above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Marcus Fairconnetue, Compliance Officer, Division of West Coast Imports, 22215 26th Avenue Southeast, Suite 210, Bothell, Washington, 98021, with a copy via electronic mail to WCID@fda.hhs.gov. If you have any questions regarding this letter, you may contact Mr. Fairconnetue via email marcus.fairconnetue@fda.hhs.gov Please reference CMS #633737 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nElaine (Xaio) Song\n\nRecipient Title\n\nOwner\n\nNorth30 LLC\n\n15552 Lake Hills Blvd # F-5\n\nBellevue, WA 98007-5928\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nJune 24, 2022\n\nWARNING LETTER\n\nRe: CMS # 633737\n\nDear Ms. Song:\n\nOn March 14 through April 8, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of North30 LLC, located at 15552 Lake Hills Blvd # F-5 Bellevue, WA 98007-5928. We also conducted an inspection April 16 through May 7, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of this significant violation, your firm is not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on April 8, 2022.\n\nYour significant violation of the FSVP regulation is as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following food products:\n\nPassion Fruit Sauce, imported from (b)(4), located in (b)(4)\n\nTaro, imported from (b)(4) located in (b)(4)\n\nMesona Extract, imported from (b)(4), located in (b)(4)\n\nWe acknowledge that during the most recent inspection, you told our investigator that your firm is expecting to transition to a model where the foods are imported by your franchise office in (b)(4) and then your firm would receive the foods after importation. As of the date of this letter, we have not received any information regarding your FSVPs or planned corrective actions. According to our records, your firm continued to import food following the end of the inspection on April 8, 2022.\n\nThe above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Marcus Fairconnetue, Compliance Officer, Division of West Coast Imports, 22215 26th Avenue Southeast, Suite 210, Bothell, Washington, 98021, with a copy via electronic mail to WCID@fda.hhs.gov. If you have any questions regarding this letter, you may contact Mr. Fairconnetue via email marcus.fairconnetue@fda.hhs.gov Please reference CMS #633737 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","North30 LLC","north30-llc-633737-06242022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth30-llc-633737-06242022","2026-10-26T08:09:34.72369+00:00","Warning Letter","Issued","2022-07-19","633737","Food & Beverages","Elaine (Xaio) Song","2026-08-20T01:45:40.604+00:00","Via Express Delivery","2022-06-24",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},419,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-24T04:00:00Z\">09\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-creek-farm-709020-09242025\">North Creek Farm\u003C\u002Fa>","Human Foods Program","PHS Act\u002FShell Egg Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Allen H. Hurst\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North Creek Farm\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1914 State Route 169\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Little Falls\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>13365\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 24, 2025\u003C\u002Fp>\u003Cp>CMS #709020\u003C\u002Fp>\u003Cp>Dear Mr. Hurst:\u003C\u002Fp>\u003Cp>On February 24, 2025, through April 14, 2025, the United States Food and Drug Administration (FDA) conducted an inspection of your shell egg farm and egg processing facility, where your shell eggs are washed, graded, and packed, located at 1914 State Route 169, Little Falls, NY 13365. During the inspection of your farm, FDA investigators observed serious violations of the Prevention of \u003Cem>Salmonella\u003C\u002Fem> Enteritidis in Shell Eggs During Production, Storage, and Transportation regulation (the Shell Egg Regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118). At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the deviations found at your farm.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings, we have determined that the shell eggs produced on your farm do not comply with the provisions of 21 CFR Part 118. Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the FD&amp;C Act, the PHS Act and the Shell Egg Regulation through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>To date, we have not received a written response to the FDA-483 and are therefore unable to evaluate any corrective actions you might have taken. Based on our review of the inspectional findings, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your farm.\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>\u003Cu>Shell Egg Regulation (21 CFR Part 118)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>1. You did not have and implement a written \u003Cem>Salmonella\u003C\u002Fem> Enteritidis (SE) Prevention Plan (SE Prevention Plan) that includes, at a minimum, the SE prevention measures required by 21 CFR 118.4. As a shell egg producer with 3,000 or more laying hens at your farm who does not sell all of your eggs directly to consumers and who produces shell eggs for the table market, you are required to comply with the Shell Egg Regulation. As part of that regulation, you are required to have an SE Prevention Plan that includes, at minimum, the SE prevention measures outlined in 21 CFR 118.4 (a) – (e), which include:\u003C\u002Fp>\u003Cp>a. \u003Cu>Pullets\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the required SE prevention measures relating to pullets. Under 21 CFR 118.4(a), these measures include procuring pullets that are SE monitored or raising pullets under SE monitored conditions. Under 21 CFR 118.4(a)(1), “SE monitored” means (among other things) that chicks are procured from SE-monitored breeder flocks that meet the National Poultry Improvement Plan's standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard. Under 21 CFR 118.4(a)(2), “SE monitored” also means that the pullet environment is tested for SE when pullets are 14-16 weeks of age.\u003C\u002Fp>\u003Cp>As discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. In addition to not having an SE Prevention Plan to address pullet procurement, you were not able to provide any documentation to indicate that your pullets were procured from SE-monitored breeder flocks or were raised under SE monitored conditions. Furthermore, you were not able to provide records indicating the pullet environment had been tested at 14-16 weeks of age. You are required to have and implement a written SE Prevention Plan that addresses all the elements of procuring SE Monitored pullets or raising pullets under SE monitored conditions.\u003C\u002Fp>\u003Cp>b. \u003Cu>Biosecurity\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the required SE prevention measures relating to biosecurity, as required by 21 CFR 118.4(b). That provision requires you to take steps to ensure that there is no introduction or transfer of SE into or among poultry houses. These biosecurity measures must include, at a minimum:\u003C\u002Fp>\u003Cp> Limiting visitors on the farm and in the poultry houses (21 CFR 118.4(b)(1));\u003Cbr> Maintaining practices that will protect against cross contamination when equipment is moved among poultry houses (21 CFR 118.4(b)(2));\u003Cbr> Maintaining practices that will protect against cross contamination when persons move between poultry houses (21 CFR 118.4(b)(3));\u003Cbr> Preventing stray poultry, wild birds, cats, and other animals from entering poultry houses (21 CFR 118.4(b)(4)); and\u003Cbr> Not allowing employees to keep birds at home (21 CFR 118.4(b)(5)).\u003C\u002Fp>\u003Cp>As discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. During the inspection, you indicated that you have implemented a biosecurity measure to restrict access to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> house with a posted sign on the door. However, you must also have a written SE Prevention Plan that implements all the biosecurity measures referenced above. We acknowledge \u003Cstrong>(b)(4)\u003C\u002Fstrong> on your farm; however, you must still take steps to prevent the introduction of SE into that poultry house.\u003C\u002Fp>\u003Cp>c. \u003Cu>Rodents, Flies, and Other Pest Control\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the required rodent, fly, and other pest control measures, as required by 21 CFR 118.4(c).\u003C\u002Fp>\u003Cp>As discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. In addition to not having an SE prevention Plan, you were not monitoring for the presence of rodents and flies by appropriate monitoring methods, as required by 21 CFR 118.4(c)(1) and 21 CFR 118.4(c)(2). For example, you stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is inadequate, as you must monitor for rodent activity within the poultry house. Furthermore, you did not monitor for fly activity within the poultry house.\u003C\u002Fp>\u003Cp>Additionally, you did not have a written SE Prevention Plan to address removal of debris within a poultry house and vegetation and debris outside a poultry house that may provide harborage for pests, as required by 21 CFR 118.4(c)(3). During the inspection, investigators observed the following conditions:\u003Cbr>• On February 27, 2025, March 27, 2025, and April 14, 2025, broken and cracked eggs were observed in a pile outside approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> feet from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> entry door to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> house. You stated you throw the eggs out for other birds or animals to eat.\u003Cbr>• Water was leaking from the ceiling onto the \u003Cstrong>(b)(4)\u003C\u002Fstrong> elevated slat area containing the feeder lines and nesting boxes.\u003Cbr>• Condensation was built up on the ceiling and pooled water was noted in the litter\u002Fscratch area throughout your laying house.\u003C\u002Fp>\u003Cp>We are concerned that the condition of your poultry house and \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas could serve as an attractant or harborage for pests, rodents, and other animals that are known vectors of pathogens. Manure should be kept as dry as possible to make it less attractive to flies (and other insects) and disposal of eggs outside your poultry house may be a food source for insects, rodents, and other pests.\u003C\u002Fp>\u003Cp>d. \u003Cu>Cleaning and Disinfection\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, cleaning and disinfection procedures for the poultry house, as required by 21 CFR 118.4(d).\u003C\u002Fp>\u003Cp>You must clean and disinfect the poultry house according to these procedures before new laying hens are added to the house, if you have had an environmental test or an egg test that was positive for SE at any point during the life of a flock that was housed in the poultry house prior to depopulation. As discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan.\u003C\u002Fp>\u003Cp>e. \u003Cu>Refrigeration\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the SE prevention measures related to refrigeration that are required by 21 CFR 118.4(e).\u003C\u002Fp>\u003Cp>As discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. In addition, you stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You must ensure eggs are held and, if applicable, transported at or below 45°F ambient temperature beginning 36 hours after time of lay, and have written procedures that address these refrigeration requirements, as required by 21 CFR 118.4(e).\u003C\u002Fp>\u003Cp>To date, we have not received a copy of your SE Prevention Plan or a response outlining corrective actions, and thus, we are unable to evaluate your preventive measures or any corrective actions you might have taken.\u003C\u002Fp>\u003Cp>2. You did not conduct environmental testing for SE in your poultry houses when laying hens were 40 to 45 weeks of age, as required by 21 CFR 118.5(a).\u003C\u002Fp>\u003Cp>Specifically, at the time of the inspection, your flock was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> weeks of age and you stated \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the required 40–45-week timeframe. Testing is important to know the SE status of your production systems. Production environments positive for SE carry a higher probability of producing SE contaminated eggs. Additionally, testing is an indicator of how well SE is controlled in a production system.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&amp;C Act, the PHS Act, and the Shell Egg Regulation.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Comments\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the items indicated above, you must have an SE plan administrator, as required by 21 CFR 118.9. The SE plan administrator is responsible for ensuring compliance with your farm’s SE prevention plan, including developing and implementing an SE prevention plan and reassessing and modifying it as necessary to ensure the requirements in 21 CFR 118.4 are met. The SE plan administrator does not have to be on-site; however, you can act as your own SE plan administrator.\u003C\u002Fp>\u003Cp>You must also maintain records documenting compliance with the SE prevention measures as required by 21 CFR 118.10. This includes keeping records documenting compliance with SE monitored pullet requirements, biosecurity, rodent and pest control, cleaning and disinfection procedures, and refrigeration requirements. All records must have the name and location of your farm, the date and time of the activity, and the signature or initials of the person performing the activity or creating the record.\u003C\u002Fp>\u003Cp>Investigators provided hard copies of resources that address various aspects of the Shell Egg Regulation, including the topics addressed in this letter, at the initiation of the inspection. Please note that resources are also available on our website at www.fda.gov\u002Feggs. For example, the December 2011 Guidance for Industry “Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” addresses topics such as rodent monitoring; the August 2022 Guidance for Industry “Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)” provides information specific to operations where layers have access to areas that are outside the poultry house; and the July 2015 Guidance for Industry “Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” provides answers to common questions about the Shell Egg Regulation. For additional hard copies, please reach out to Lisa Thursam, Compliance Officer, at the address provided below.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply via email to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Lisa Thursam, Compliance Officer, at Lisa.Thursam@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Lisa Thursam, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Lisa Thursam, Compliance Officer, via email at Lisa.Thursam@fda.hhs.gov. Please include CMS reference #709020 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Thomas Kuntz\u003Cbr>Acting Deputy Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Allen H. Hurst\n\nRecipient Title\n\nOwner\n\nNorth Creek Farm\n\n1914 State Route 169\n\nLittle Falls, NY 13365\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nSeptember 24, 2025\nCMS #709020\nDear Mr. Hurst:\nOn February 24, 2025, through April 14, 2025, the United States Food and Drug Administration (FDA) conducted an inspection of your shell egg farm and egg processing facility, where your shell eggs are washed, graded, and packed, located at 1914 State Route 169, Little Falls, NY 13365. During the inspection of your farm, FDA investigators observed serious violations of the Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation regulation (the Shell Egg Regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118). At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the deviations found at your farm.\nBased on FDA’s inspectional findings, we have determined that the shell eggs produced on your farm do not comply with the provisions of 21 CFR Part 118. Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the FD&C Act, the PHS Act and the Shell Egg Regulation through links on FDA’s home page at www.fda.gov.\nTo date, we have not received a written response to the FDA-483 and are therefore unable to evaluate any corrective actions you might have taken. Based on our review of the inspectional findings, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your farm.\nYour significant violations are as follows:\nShell Egg Regulation (21 CFR Part 118)\n1. You did not have and implement a written Salmonella Enteritidis (SE) Prevention Plan (SE Prevention Plan) that includes, at a minimum, the SE prevention measures required by 21 CFR 118.4. As a shell egg producer with 3,000 or more laying hens at your farm who does not sell all of your eggs directly to consumers and who produces shell eggs for the table market, you are required to comply with the Shell Egg Regulation. As part of that regulation, you are required to have an SE Prevention Plan that includes, at minimum, the SE prevention measures outlined in 21 CFR 118.4 (a) – (e), which include:\na. Pullets\nA written SE Prevention Plan must include, among other things, the required SE prevention measures relating to pullets. Under 21 CFR 118.4(a), these measures include procuring pullets that are SE monitored or raising pullets under SE monitored conditions. Under 21 CFR 118.4(a)(1), “SE monitored” means (among other things) that chicks are procured from SE-monitored breeder flocks that meet the National Poultry Improvement Plan's standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard. Under 21 CFR 118.4(a)(2), “SE monitored” also means that the pullet environment is tested for SE when pullets are 14-16 weeks of age.\nAs discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. In addition to not having an SE Prevention Plan to address pullet procurement, you were not able to provide any documentation to indicate that your pullets were procured from SE-monitored breeder flocks or were raised under SE monitored conditions. Furthermore, you were not able to provide records indicating the pullet environment had been tested at 14-16 weeks of age. You are required to have and implement a written SE Prevention Plan that addresses all the elements of procuring SE Monitored pullets or raising pullets under SE monitored conditions.\nb. Biosecurity\nA written SE Prevention Plan must include, among other things, the required SE prevention measures relating to biosecurity, as required by 21 CFR 118.4(b). That provision requires you to take steps to ensure that there is no introduction or transfer of SE into or among poultry houses. These biosecurity measures must include, at a minimum:\n Limiting visitors on the farm and in the poultry houses (21 CFR 118.4(b)(1));\n Maintaining practices that will protect against cross contamination when equipment is moved among poultry houses (21 CFR 118.4(b)(2));\n Maintaining practices that will protect against cross contamination when persons move between poultry houses (21 CFR 118.4(b)(3));\n Preventing stray poultry, wild birds, cats, and other animals from entering poultry houses (21 CFR 118.4(b)(4)); and\n Not allowing employees to keep birds at home (21 CFR 118.4(b)(5)).\nAs discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. During the inspection, you indicated that you have implemented a biosecurity measure to restrict access to your (b)(4) house with a posted sign on the door. However, you must also have a written SE Prevention Plan that implements all the biosecurity measures referenced above. We acknowledge (b)(4) on your farm; however, you must still take steps to prevent the introduction of SE into that poultry house.\nc. Rodents, Flies, and Other Pest Control\nA written SE Prevention Plan must include, among other things, the required rodent, fly, and other pest control measures, as required by 21 CFR 118.4(c).\nAs discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. In addition to not having an SE prevention Plan, you were not monitoring for the presence of rodents and flies by appropriate monitoring methods, as required by 21 CFR 118.4(c)(1) and 21 CFR 118.4(c)(2). For example, you stated (b)(4). This is inadequate, as you must monitor for rodent activity within the poultry house. Furthermore, you did not monitor for fly activity within the poultry house.\nAdditionally, you did not have a written SE Prevention Plan to address removal of debris within a poultry house and vegetation and debris outside a poultry house that may provide harborage for pests, as required by 21 CFR 118.4(c)(3). During the inspection, investigators observed the following conditions:\n• On February 27, 2025, March 27, 2025, and April 14, 2025, broken and cracked eggs were observed in a pile outside approximately (b)(4) feet from the (b)(4) entry door to your (b)(4) house. You stated you throw the eggs out for other birds or animals to eat.\n• Water was leaking from the ceiling onto the (b)(4) elevated slat area containing the feeder lines and nesting boxes.\n• Condensation was built up on the ceiling and pooled water was noted in the litter\u002Fscratch area throughout your laying house.\nWe are concerned that the condition of your poultry house and (b)(4) areas could serve as an attractant or harborage for pests, rodents, and other animals that are known vectors of pathogens. Manure should be kept as dry as possible to make it less attractive to flies (and other insects) and disposal of eggs outside your poultry house may be a food source for insects, rodents, and other pests.\nd. Cleaning and Disinfection\nA written SE Prevention Plan must include, among other things, cleaning and disinfection procedures for the poultry house, as required by 21 CFR 118.4(d).\nYou must clean and disinfect the poultry house according to these procedures before new laying hens are added to the house, if you have had an environmental test or an egg test that was positive for SE at any point during the life of a flock that was housed in the poultry house prior to depopulation. As discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan.\ne. Refrigeration\nA written SE Prevention Plan must include, among other things, the SE prevention measures related to refrigeration that are required by 21 CFR 118.4(e).\nAs discussed above, you indicated during the inspection that you did not have a written SE Prevention Plan. In addition, you stated (b)(4). You must ensure eggs are held and, if applicable, transported at or below 45°F ambient temperature beginning 36 hours after time of lay, and have written procedures that address these refrigeration requirements, as required by 21 CFR 118.4(e).\nTo date, we have not received a copy of your SE Prevention Plan or a response outlining corrective actions, and thus, we are unable to evaluate your preventive measures or any corrective actions you might have taken.\n2. You did not conduct environmental testing for SE in your poultry houses when laying hens were 40 to 45 weeks of age, as required by 21 CFR 118.5(a).\nSpecifically, at the time of the inspection, your flock was approximately (b)(4) weeks of age and you stated (b)(4) during the required 40–45-week timeframe. Testing is important to know the SE status of your production systems. Production environments positive for SE carry a higher probability of producing SE contaminated eggs. Additionally, testing is an indicator of how well SE is controlled in a production system.\nThis letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&C Act, the PHS Act, and the Shell Egg Regulation.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\nAdditional Comments\nIn addition to the items indicated above, you must have an SE plan administrator, as required by 21 CFR 118.9. The SE plan administrator is responsible for ensuring compliance with your farm’s SE prevention plan, including developing and implementing an SE prevention plan and reassessing and modifying it as necessary to ensure the requirements in 21 CFR 118.4 are met. The SE plan administrator does not have to be on-site; however, you can act as your own SE plan administrator.\nYou must also maintain records documenting compliance with the SE prevention measures as required by 21 CFR 118.10. This includes keeping records documenting compliance with SE monitored pullet requirements, biosecurity, rodent and pest control, cleaning and disinfection procedures, and refrigeration requirements. All records must have the name and location of your farm, the date and time of the activity, and the signature or initials of the person performing the activity or creating the record.\nInvestigators provided hard copies of resources that address various aspects of the Shell Egg Regulation, including the topics addressed in this letter, at the initiation of the inspection. Please note that resources are also available on our website at www.fda.gov\u002Feggs. For example, the December 2011 Guidance for Industry “Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” addresses topics such as rodent monitoring; the August 2022 Guidance for Industry “Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)” provides information specific to operations where layers have access to areas that are outside the poultry house; and the July 2015 Guidance for Industry “Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” provides answers to common questions about the Shell Egg Regulation. For additional hard copies, please reach out to Lisa Thursam, Compliance Officer, at the address provided below.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\nPlease send your reply via email to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Lisa Thursam, Compliance Officer, at Lisa.Thursam@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Lisa Thursam, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Lisa Thursam, Compliance Officer, via email at Lisa.Thursam@fda.hhs.gov. Please include CMS reference #709020 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nThomas Kuntz\nActing Deputy Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","North Creek Farm","north-creek-farm-709020-09242025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-creek-farm-709020-09242025","2026-10-26T08:09:34.649997+00:00","2025-12-16","709020","Mr. Allen H. Hurst","2026-08-19T16:09:22.517+00:00","United Parcel Service","2025-09-24",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":19,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":72,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},1186,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2024-10-30T15:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-29T04:00:00Z\">10\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-disposable-695211-10292024\">North Disposable\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402220\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>North Disposable\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>21746 73rd Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vero Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32966\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:marketing@northdisposable.com\"> marketing@northdisposable.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To Whom It May Concern:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fnorthdisposable.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: V-Touch 30K Disposable - Jolly Rancher, Halo Vapor Synix 30K Bluetooth Vape - Black Cherry, and South Connect 35K Disposable - Grape Blow Pop.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds these products particularly concerning because the product labeling and\u002For advertising for V-Touch 30K Disposable, Halo Vapor Synix 30K Bluetooth Vape, and South Connect 35K Disposable (see Exhibit A) may be attractive to youth by imitating a smartphone or other smart technology (see Exhibit B).\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F695211-N.%20Disposable.png\" alt=\"695211-Watch and Cellphone\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>In particular, youth and young adults may be attracted to the products’ design and functionalities imitating smart phones and other smart technology, including:\u003C\u002Fp>\n\n\u003Cp>V-Touch 30K Disposable\u003Cbr>\n• “Bluetooth Connectivity: Sync effortlessly with your smartphone”\u003Cbr>\n• “Call Functionality: Make and receive calls directly from your vape”\u003Cbr>\n• “Built-in Audio Player: Enjoy music on the go”\u003Cbr>\n• “Find My Phone: Never lose your phone again”\u003Cbr>\n• “Interactive Touch Screen: Easy navigation and control”\u003Cbr>\n• “Social Media &amp; Text Integration: Stay connected with friends”\u003C\u002Fp>\n\n\u003Cp>Halo Vapor Synix 30K Bluetooth Vape\u003Cbr>\n• “Bluetooth Connectivity: Stay seamlessly connected with built-in Bluetooth, enabling pairing with your smartphone for additional convenience and control.”\u003Cbr>\n• “AI Chat: Revolutionize your vaping experience with AI chat functionality, adding an interactive and engaging element to your sessions.”\u003C\u002Fp>\n\n\u003Cp>South Connect 35K Disposable\u003Cbr>\n• “Downloadable App: Customize settings and access additional features.”\u003Cbr>\n• “Built-in Games: Three built-in games for entertainment.”\u003Cbr>\n• “Upload Wallpapers: Personalize with custom wallpapers.”\u003Cbr>\n• “Speaker: Enjoy music and audio during sessions.”\u003C\u002Fp>\n\n\u003Cp>Further, the products’ design may be attractive to youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402220, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402220\n\nProduct:\n\nTobacco\n\nRecipient:\n\nNorth Disposable\n\n21746 73rd Place\n\nVero Beach, FL 32966\n\nUnited States\n\nmarketing@northdisposable.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 29, 2024\n\nWARNING LETTER\n\nTo Whom It May Concern:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fnorthdisposable.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: V-Touch 30K Disposable - Jolly Rancher, Halo Vapor Synix 30K Bluetooth Vape - Black Cherry, and South Connect 35K Disposable - Grape Blow Pop.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nAdditional Considerations\n\nFDA finds these products particularly concerning because the product labeling and\u002For advertising for V-Touch 30K Disposable, Halo Vapor Synix 30K Bluetooth Vape, and South Connect 35K Disposable (see Exhibit A) may be attractive to youth by imitating a smartphone or other smart technology (see Exhibit B).\n\nIn particular, youth and young adults may be attracted to the products’ design and functionalities imitating smart phones and other smart technology, including:\n\nV-Touch 30K Disposable\n\n• “Bluetooth Connectivity: Sync effortlessly with your smartphone”\n\n• “Call Functionality: Make and receive calls directly from your vape”\n\n• “Built-in Audio Player: Enjoy music on the go”\n\n• “Find My Phone: Never lose your phone again”\n\n• “Interactive Touch Screen: Easy navigation and control”\n\n• “Social Media & Text Integration: Stay connected with friends”\n\nHalo Vapor Synix 30K Bluetooth Vape\n\n• “Bluetooth Connectivity: Stay seamlessly connected with built-in Bluetooth, enabling pairing with your smartphone for additional convenience and control.”\n\n• “AI Chat: Revolutionize your vaping experience with AI chat functionality, adding an interactive and engaging element to your sessions.”\n\nSouth Connect 35K Disposable\n\n• “Downloadable App: Customize settings and access additional features.”\n\n• “Built-in Games: Three built-in games for entertainment.”\n\n• “Upload Wallpapers: Personalize with custom wallpapers.”\n\n• “Speaker: Enjoy music and audio during sessions.”\n\nFurther, the products’ design may be attractive to youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402220, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","North Disposable","north-disposable-695211-10292024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-disposable-695211-10292024","2026-10-26T08:09:34.688978+00:00","2024-10-30","695211","Tobacco","2026-08-19T21:16:46.656+00:00","VIA UPS and Electronic Mail","RW2402220","2024-10-29",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":26,"closeout_date":19,"issuing_office":91,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},1980,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-07T04:00:00Z\">07\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-vapor-company-llc-648568-07072023\">Northland Vapor Company, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West I ","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brett T. Erpelding\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Northland Vapor Company, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>201 Fifth Street North, 16th Floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fargo\u003C\u002Fspan>, \u003Cspan>ND\u003C\u002Fspan> \u003Cspan>58102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 7, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer to CMS 648568\u003Cbr>\n\u003Cbr>\nBradley E. Erpelding, President and Chief Financial Officer\u003Cbr>\nCody Townsend, Executive Vice President of Retail\u003Cbr>\n\u003Cbr>\nDear Messrs. Erpelding and Townsend:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your Wonky Confections, LLC facility, which manufactures ready-to-eat (RTE) human food products containing Delta-8 tetrahydrocannabinol (THC), located at 2721 20th Avenue South, Unit J, Moorhead, Minnesota, on November 8-9, 16, 28, and December 7, 2022.\u003C\u002Fp>\n\n\u003Cp>Based on the inspection, a review of the product labels collected during the inspection, and laboratory analysis of your products, FDA has determined that your “Death by Gummy Bears” and “Wonky Weeds” gummy bear products you manufactured in your facility are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. § 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Additionally, we have determined that the RTE food products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the FD&amp;C Act, 21 U.S.C. § 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection FDA issued a Form FDA-483 (FDA-483), Inspectional Observations, listing the deviations found at your facility. We also received your response dated December 19, 2022, which included a summary of corrective actions taken or planned by your firm. Based on our review of the inspectional findings and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\u003Cbr>\n\u003Cbr>\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003C\u002Fp>\n\n\u003Cp>FDA has observed a proliferation of products containing the cannabinoid Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: (1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that puts public health at risk; (2) FDA has received adverse event reports involving Delta-8 THC containing products; (3) Delta-8 THC has psychoactive and intoxicating effects; (4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and (5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter informs you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods (section 402(a)(2)(C)(i) of the FD&amp;C Act)\u003C\u002Fstrong>\u003Cbr>\nAccording to your product labeling, your “Death by Gummy Bears” and “Wonky Weeds” gummy bear products are foods to which Delta-8 THC has been added. In addition, FDA confirmed through laboratory analysis that samples of these products contain Delta-8 THC.\u003C\u002Fp>\n\n\u003Cp>As defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. § 321(s), the term \"food additive\" refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. § 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. § 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your “Death by Gummy Bears” and “Wonky Weeds” gummy bear products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods (section 402(a)(4) of the FD&amp;C Act)\u003C\u002Fstrong>\u003Cbr>\nYour RTE food products are adulterated within the meaning of section 402(a)(4) of the FD&amp;C Act, 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby the food products may have become contaminated with filth, or whereby they may have been rendered injurious to health. During our inspection of your establishment, FDA investigators found violations of the Current Good Manufacturing Practice regulations for human foods under 21 CFR Part 117, subpart B. The significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not take reasonable precautions and measures to ensure that all persons working in direct contact with food wash hands thoroughly (and sanitize if necessary to protect against contamination with undesirable microorganisms) after each absence from the workstation and at any other time when hands may have become soiled or contaminated, as required by 21 CFR 117.10(b)(3). Specifically, on November 8 and November 9, 2022, \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees were observed not washing and sanitizing hands prior to donning gloves before separating by hand the RTE gummy candy products from excess sugar and hand-packing the products into finished product packaging.\u003C\u002Fp>\n\n\u003Cp>In your response you stated you have implemented a \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure that instructs employees to wash hands in a number of situations, including but not limited to, the following situations: before starting work, before putting on or changing gloves, and after any time the hands may become contaminated. You state you have begun training employees in the new procedure, including posting signs with a step-by-step \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure by each \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink. You state the process will be implemented by January 31, 2023. We will verify the adequacy of this corrective action during a future inspection.\u003C\u002Fp>\n\n\u003Cp>2. You did not provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> facilities designed to ensure that an employee's hands are not a source of contamination of food, food-contact surfaces, or food-packaging materials, by providing facilities that are adequate, convenient, and furnish running water at a suitable temperature, as required by 21 CFR 117.37(e). Specifically, your facility is equipped with only one \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink, located in the employee restroom, which is inaccessible during bathroom occupancy and shared by approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees. This \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink is in a separate area that is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> feet away from the production area.\u003C\u002Fp>\n\n\u003Cp>In your response you stated you will begin drafting plans for the installation of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink, which will be in the same room where manufacturing operations occur. Additionally, you stated you have contacted a plumber and discussed plans for the following services: installation of motion sensor operated faucets on both the current and the new \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink and the installation of automatic soap dispensers at both \u003Cstrong>(b)(4)\u003C\u002Fstrong> stations. You also state that until these operations have been completed, employees will be instructed to use paper towels to turn off the faucet and open the door, if necessary. You did not provide in your response an update on the installation process or a timeline for completion, nor did you include invoices or other records demonstrating that you have been in contact with a plumber. We will verify the adequacy of this corrective action during a future inspection.\u003C\u002Fp>\n\n\u003Cp>3. You did not clean food-contact surfaces in a manner that protects against allergen cross-contact and contamination, as required by 21 CFR 117.35(a). Specifically, on November 9, 2022, employees were observed washing equipment and utensils used in the production of the RTE gummy candy products with detergent but not sanitizing them. Cleaned utensils are placed onto a metal drying rack; however, a measuring pitcher was observed on the drying rack not inverted and containing pooled water. The pitcher also contained residual material that you identified as THC distillate.\u003C\u002Fp>\n\n\u003Cp>In your response you stated you would prepare, implement, and train employees on a new SOP on appropriate dishwashing and sanitizing practices. You also said the SOP will include signage placed above the three-compartment sink to remind employees to wash with detergent, rinse with warm clean water, and then sanitize and soak dishes. You stated you will also employ the use of test strips to double-check the concentration of sanitizer in the water. We will verify the adequacy of this corrective action during a future inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Food\u003C\u002Fstrong>\u003Cbr>\nUnder section 201(qq) of the FD&amp;C Act, 21 U.S.C. § 321(qq), soy is considered a “major food allergen.” A food is misbranded under section 403(w) of the FD&amp;C Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 343(w)(1)(A); or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived, e.g., “Whey (Milk),” except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the FD&amp;C Act, 21 U.S.C. § 343(w)(1)(B).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FDA’s inspection found that during the manufacturing of your gummy products, you use Pam spray as a releasing agent, which contains the allergen “soy.” Your “Wonky Weeds” and “Death by Gummy Bears” gummy bear products are misbranded within the meaning of section 403(w) of the FD&amp;C Act, 21 U.S.C. § 343(w), in that the finished product label fails to declare a major food allergen (soy).\u003C\u002Fp>\n\n\u003Cp>In your response you stated that you are exploring alternatives to the use of Pam spray and that, should you continue to use Pam spray, you will ensure the use of such product and its inclusion of soy will be referenced on product labels. However, you did not provide a copy of a revised label declaring the allergen soy and, therefore, we are unable to determine the adequacy of your corrective action.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Register Food Facility\u003C\u002Fstrong>\u003Cbr>\nIn addition, FDA has determined that your facility located at 2721 20th Avenue South, Unit J, Moorhead, Minnesota, 56560, is subject to the food facility registration requirement in section 415 of the FD&amp;C Act, 21 U.S.C. § 350d, and our implementing regulation at 21 CFR Part 1, Subpart H. Our records indicate that as of the date of this letter your facility has not been registered with FDA. The failure to register a facility as required is a prohibited act under section 301(dd) of the FD&amp;C Act, 21 U.S.C. § 331(dd).\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute comply with the law.\u003Cbr>\n\u003Cbr>\nWe request that the owner, operator, or agent in charge of this facility, or an individual authorized by this facility's owner, operator, or agent in charge, register the facility with FDA within 30 working days of the date of this letter. Food facility registration guidance is available online at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions. Registration may be accomplished online at http:\u002F\u002Fwww.access.fda.gov. You must submit your registration or registration renewal to FDA electronically, unless FDA has granted you a waiver under 21 CFR 1.245 (21 CFR 1.231(a)(4)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003Cbr>\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the cause(s) of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days from your receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration, Attention: Compliance Officer Boun Xiong, 250 Marquette Avenue, Suite 600, Minneapolis, Minnesota 55401. If you have any questions about this letter, please contact Mr. Xiong at (414) 326-3976 or via email at boun.xiong@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Chris van Twuyver\u003Cbr>\nProgram Division Director, West Division 1\u003Cbr>\nOffice of Human and Animal Food Operations\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act, 21 U.S.C. § 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food; (2) pesticide chemicals; (3) color additives; (4) substances used in accordance with a “prior sanction,” i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act; (5) new animal drugs; and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nBrett T. Erpelding\n\nRecipient Title\n\nChief Executive Officer\n\nNorthland Vapor Company, LLC\n\n201 Fifth Street North, 16th Floor\n\nFargo, ND 58102\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West I\n\nUnited States\n\nJuly 7, 2023\n\nWARNING LETTER\n\nRefer to CMS 648568\n\nBradley E. Erpelding, President and Chief Financial Officer\n\nCody Townsend, Executive Vice President of Retail\n\nDear Messrs. Erpelding and Townsend:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your Wonky Confections, LLC facility, which manufactures ready-to-eat (RTE) human food products containing Delta-8 tetrahydrocannabinol (THC), located at 2721 20th Avenue South, Unit J, Moorhead, Minnesota, on November 8-9, 16, 28, and December 7, 2022.\n\nBased on the inspection, a review of the product labels collected during the inspection, and laboratory analysis of your products, FDA has determined that your “Death by Gummy Bears” and “Wonky Weeds” gummy bear products you manufactured in your facility are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. § 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Additionally, we have determined that the RTE food products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the FD&C Act, 21 U.S.C. § 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\n\nAt the conclusion of the inspection FDA issued a Form FDA-483 (FDA-483), Inspectional Observations, listing the deviations found at your facility. We also received your response dated December 19, 2022, which included a summary of corrective actions taken or planned by your firm. Based on our review of the inspectional findings and the response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nFDA has observed a proliferation of products containing the cannabinoid Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: (1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that puts public health at risk; (2) FDA has received adverse event reports involving Delta-8 THC containing products; (3) Delta-8 THC has psychoactive and intoxicating effects; (4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and (5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter informs you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\n\nAdulterated Human Foods (section 402(a)(2)(C)(i) of the FD&C Act)\n\nAccording to your product labeling, your “Death by Gummy Bears” and “Wonky Weeds” gummy bear products are foods to which Delta-8 THC has been added. In addition, FDA confirmed through laboratory analysis that samples of these products contain Delta-8 THC.\n\nAs defined in section 201(s) of the FD&C Act, 21 U.S.C. § 321(s), the term \"food additive\" refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.1\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. § 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. § 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your “Death by Gummy Bears” and “Wonky Weeds” gummy bear products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\n\nAdulterated Human Foods (section 402(a)(4) of the FD&C Act)\n\nYour RTE food products are adulterated within the meaning of section 402(a)(4) of the FD&C Act, 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby the food products may have become contaminated with filth, or whereby they may have been rendered injurious to health. During our inspection of your establishment, FDA investigators found violations of the Current Good Manufacturing Practice regulations for human foods under 21 CFR Part 117, subpart B. The significant violations are as follows:\n\n1. You did not take reasonable precautions and measures to ensure that all persons working in direct contact with food wash hands thoroughly (and sanitize if necessary to protect against contamination with undesirable microorganisms) after each absence from the workstation and at any other time when hands may have become soiled or contaminated, as required by 21 CFR 117.10(b)(3). Specifically, on November 8 and November 9, 2022, (b)(4) employees were observed not washing and sanitizing hands prior to donning gloves before separating by hand the RTE gummy candy products from excess sugar and hand-packing the products into finished product packaging.\n\nIn your response you stated you have implemented a (b)(4) procedure that instructs employees to wash hands in a number of situations, including but not limited to, the following situations: before starting work, before putting on or changing gloves, and after any time the hands may become contaminated. You state you have begun training employees in the new procedure, including posting signs with a step-by-step (b)(4) procedure by each (b)(4) sink. You state the process will be implemented by January 31, 2023. We will verify the adequacy of this corrective action during a future inspection.\n\n2. You did not provide (b)(4) facilities designed to ensure that an employee's hands are not a source of contamination of food, food-contact surfaces, or food-packaging materials, by providing facilities that are adequate, convenient, and furnish running water at a suitable temperature, as required by 21 CFR 117.37(e). Specifically, your facility is equipped with only one (b)(4) sink, located in the employee restroom, which is inaccessible during bathroom occupancy and shared by approximately (b)(4) employees. This (b)(4) sink is in a separate area that is approximately (b)(4) feet away from the production area.\n\nIn your response you stated you will begin drafting plans for the installation of a new (b)(4) sink, which will be in the same room where manufacturing operations occur. Additionally, you stated you have contacted a plumber and discussed plans for the following services: installation of motion sensor operated faucets on both the current and the new (b)(4) sink and the installation of automatic soap dispensers at both (b)(4) stations. You also state that until these operations have been completed, employees will be instructed to use paper towels to turn off the faucet and open the door, if necessary. You did not provide in your response an update on the installation process or a timeline for completion, nor did you include invoices or other records demonstrating that you have been in contact with a plumber. We will verify the adequacy of this corrective action during a future inspection.\n\n3. You did not clean food-contact surfaces in a manner that protects against allergen cross-contact and contamination, as required by 21 CFR 117.35(a). Specifically, on November 9, 2022, employees were observed washing equipment and utensils used in the production of the RTE gummy candy products with detergent but not sanitizing them. Cleaned utensils are placed onto a metal drying rack; however, a measuring pitcher was observed on the drying rack not inverted and containing pooled water. The pitcher also contained residual material that you identified as THC distillate.\n\nIn your response you stated you would prepare, implement, and train employees on a new SOP on appropriate dishwashing and sanitizing practices. You also said the SOP will include signage placed above the three-compartment sink to remind employees to wash with detergent, rinse with warm clean water, and then sanitize and soak dishes. You stated you will also employ the use of test strips to double-check the concentration of sanitizer in the water. We will verify the adequacy of this corrective action during a future inspection.\n\nMisbranded Food\n\nUnder section 201(qq) of the FD&C Act, 21 U.S.C. § 321(qq), soy is considered a “major food allergen.” A food is misbranded under section 403(w) of the FD&C Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the FD&C Act, 21 U.S.C. § 343(w)(1)(A); or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived, e.g., “Whey (Milk),” except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the FD&C Act, 21 U.S.C. § 343(w)(1)(B).\n\nFDA’s inspection found that during the manufacturing of your gummy products, you use Pam spray as a releasing agent, which contains the allergen “soy.” Your “Wonky Weeds” and “Death by Gummy Bears” gummy bear products are misbranded within the meaning of section 403(w) of the FD&C Act, 21 U.S.C. § 343(w), in that the finished product label fails to declare a major food allergen (soy).\n\nIn your response you stated that you are exploring alternatives to the use of Pam spray and that, should you continue to use Pam spray, you will ensure the use of such product and its inclusion of soy will be referenced on product labels. However, you did not provide a copy of a revised label declaring the allergen soy and, therefore, we are unable to determine the adequacy of your corrective action.\n\nFailure to Register Food Facility\n\nIn addition, FDA has determined that your facility located at 2721 20th Avenue South, Unit J, Moorhead, Minnesota, 56560, is subject to the food facility registration requirement in section 415 of the FD&C Act, 21 U.S.C. § 350d, and our implementing regulation at 21 CFR Part 1, Subpart H. Our records indicate that as of the date of this letter your facility has not been registered with FDA. The failure to register a facility as required is a prohibited act under section 301(dd) of the FD&C Act, 21 U.S.C. § 331(dd).\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute comply with the law.\n\nWe request that the owner, operator, or agent in charge of this facility, or an individual authorized by this facility's owner, operator, or agent in charge, register the facility with FDA within 30 working days of the date of this letter. Food facility registration guidance is available online at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidance-regulation-food-and-dietary-supplements\u002Fregistration-food-facilities-and-other-submissions. Registration may be accomplished online at http:\u002F\u002Fwww.access.fda.gov. You must submit your registration or registration renewal to FDA electronically, unless FDA has granted you a waiver under 21 CFR 1.245 (21 CFR 1.231(a)(4)).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the cause(s) of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days from your receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration, Attention: Compliance Officer Boun Xiong, 250 Marquette Avenue, Suite 600, Minneapolis, Minnesota 55401. If you have any questions about this letter, please contact Mr. Xiong at (414) 326-3976 or via email at boun.xiong@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Chris van Twuyver\n\nProgram Division Director, West Division 1\n\nOffice of Human and Animal Food Operations\n\n___________________________\n\n1 Under section 201(s) of the FD&C Act, 21 U.S.C. § 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food; (2) pesticide chemicals; (3) color additives; (4) substances used in accordance with a “prior sanction,” i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act; (5) new animal drugs; and (6) dietary ingredients in or intended for use in a dietary supplement.","Northland Vapor Company, LLC","northland-vapor-company-llc-648568-07072023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-vapor-company-llc-648568-07072023","2026-10-26T08:09:34.916883+00:00","2023-07-25","648568","Division of Human and Animal Food Operations West I","Brett T. Erpelding","2026-08-20T00:51:48.082+00:00","VIA UPS","2023-07-07",{"id":97,"raw":98,"subject":59,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":111,"body_fetched_at":112,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},3063,[99,100,101,58,59,13,13,13],"\u003Ctime datetime=\"2021-10-26T13:20:00Z\">10\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-20T04:00:00Z\">10\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-vapor-company-619673-10202021\">Northland Vapor Company\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brett Erpelding\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Northland Vapor Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>115 8th Street South\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Moorhead\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>56560\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@northlandvapor.com\"> info@northlandvapor.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@northlandvapor.zendesk.com\"> support@northlandvapor.zendesk.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 20, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Brett Erpelding:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fnorthlandvapor.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fnorthlandvapor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Mint Chip, Jungle N°4, and Loopies.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 800 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0003045 on September 9, 2020. However, FDA issued negative actions for PMTA STN PM0003045in the form of a Marketing Denial Order determinations on September 17, 2021 which covers 140 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0003045 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003Cbr>\n\u003Cbr>\nPlease note your reference number, RW2101662, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Northland Vapor Company, LLC\u003Cbr>\n4225 38th St S Ste 108\u003Cbr>\nFargo, ND 58104-7573\u003C\u002Fp>\n\n\u003Cp>Withheld for Privacy\u003Cbr>\na9da0c324bff430fad9ce769d2e448a9.protect@withheldforprivacy.com\u003C\u002Fp>\n\n\u003Cp>NameCheap, Inc.\u003Cbr>\nabuse@namecheap.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nBrett Erpelding\n\nNorthland Vapor Company\n\n115 8th Street South\n\nMoorhead, MN 56560\n\nUnited States\n\ninfo@northlandvapor.com\n\nsupport@northlandvapor.zendesk.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 20, 2021\n\nWARNING LETTER\n\nDear Brett Erpelding:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fnorthlandvapor.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fnorthlandvapor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Mint Chip, Jungle N°4, and Loopies.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 800 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0003045 on September 9, 2020. However, FDA issued negative actions for PMTA STN PM0003045in the form of a Marketing Denial Order determinations on September 17, 2021 which covers 140 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0003045 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101662, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nNorthland Vapor Company, LLC\n\n4225 38th St S Ste 108\n\nFargo, ND 58104-7573\n\nWithheld for Privacy\n\na9da0c324bff430fad9ce769d2e448a9.protect@withheldforprivacy.com\n\nNameCheap, Inc.\n\nabuse@namecheap.com\n\nShopify, Inc.\n\nabuse@shopify.com","Northland Vapor Company","northland-vapor-company-619673-10202021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-vapor-company-619673-10202021","2026-10-26T08:09:34.862031+00:00","2021-10-26","619673","Brett Erpelding","2026-08-20T02:29:44.153+00:00","2021-10-20",{"id":115,"raw":116,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":127,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":132,"closeout_date":19,"issuing_office":120,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},2337,[117,118,119,120,121,13,13,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022\">BergaMet North America LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jay Decker\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BergaMet North America LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6445 S. Tenaya Way Suite B110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89113-1989\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:orders@bergametna.com\"> orders@bergametna.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636315\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jay Decker:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\u003Cbr>\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-inflammatory”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Reduces cholesterol”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n\u003Cbr>\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;On a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\u003Cbr>\n&nbsp; o “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\u003Cbr>\n&nbsp; o “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\u003Cbr>\n&nbsp; o You also endorsed the following responses to your post by liking them:\u003Cbr>\n&nbsp; &nbsp; 􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Yes!! Mine went down 38 points.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n\u003Cbr>\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jay Decker\n\nBergaMet North America LLC\n\n6445 S. Tenaya Way Suite B110\n\nLas Vegas, NV 89113-1989\n\nUnited States\n\norders@bergametna.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636315\n\nDear Mr. Jay Decker:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\n\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\n\n“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\n\n“Anti-inflammatory”\n\n“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\n\n“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\n\n“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\n\nOn your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\n\n“Reduces cholesterol”\n\n“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\n\nOn your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\n\n“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\n\nYour websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\n\n“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\n\nOn your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\n\nOn a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\n\no “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\n\no “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\n\no “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\n\no You also endorsed the following responses to your post by liking them:\n\n􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\n\n“Yes!! Mine went down 38 points.”\n\nYour Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","BergaMet North America LLC","bergamet-north-america-llc-636315-11142022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022","2026-10-26T08:08:03.414177+00:00","2022-11-17","636315","Dietary SupplementsDrugs","Mr. Jay Decker","2026-08-20T01:25:33.357+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":138,"raw":139,"subject":59,"body_html":143,"body_text":144,"firm_name":145,"letter_id":146,"created_at":106,"fei_number":19,"letter_url":147,"updated_at":148,"action_type":22,"case_status":23,"posted_date":149,"marcs_cms_no":150,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":151,"body_fetched_at":152,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},3409,[140,141,142,58,59,13,13,13],"\u003Ctime datetime=\"2021-04-13T13:20:00Z\">04\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-09T04:00:00Z\">04\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthwest-vapors-llc-614219-04092021\">Northwest Vapors LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William Krause Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Northwest Vapors LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>201 Port Ave Ste 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Helens\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bill@nwvapors.com\"> bill@nwvapors.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:will@nwvapors.com\"> will@nwvapors.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@nwvapors.com\"> support@nwvapors.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@nwvapors.com\"> sales@nwvapors.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 9, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear William Krause Jr.:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.nwvapors.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.nwvapors.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Taste e-Liquid Toasted Almond and Summit Cloud Peak.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,400 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101568, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at \u003Cspan>(301) 796-9235\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Northwest Vapors LLC\u003Cbr>\nAttn: William Krause Jr.\u003Cbr>\n4515 Cordon Rd Ne\u003Cbr>\nSalem, OR 97305\u003C\u002Fp>\n\n\u003Cp>The Endurance International Group, Inc.\u003Cbr>\nwhois@hostmaster.com\u003C\u002Fp>\n\n\u003Cp>FastDomain Inc.\u003Cbr>\nsupport@hostmonster.com\u003C\u002Fp>\n\n\u003Cp>Unified Layer\u003Cbr>\nabuse@unifiedlayer.com\u003Cbr>\nabuse@bluehost.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nWilliam Krause Jr.\n\nNorthwest Vapors LLC\n\n201 Port Ave Ste 4\n\nSaint Helens, OR 97051\n\nUnited States\n\nbill@nwvapors.com\n\nwill@nwvapors.com\n\nsupport@nwvapors.com\n\nsales@nwvapors.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 9, 2021\n\nWARNING LETTER\n\nDear William Krause Jr.:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.nwvapors.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.nwvapors.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Taste e-Liquid Toasted Almond and Summit Cloud Peak.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,400 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101568, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nNorthwest Vapors LLC\n\nAttn: William Krause Jr.\n\n4515 Cordon Rd Ne\n\nSalem, OR 97305\n\nThe Endurance International Group, Inc.\n\nwhois@hostmaster.com\n\nFastDomain Inc.\n\nsupport@hostmonster.com\n\nUnified Layer\n\nabuse@unifiedlayer.com\n\nabuse@bluehost.com","Northwest Vapors LLC","northwest-vapors-llc-614219-04092021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthwest-vapors-llc-614219-04092021","2026-10-26T08:09:34.992672+00:00","2021-04-13","614219","William Krause Jr.","2026-08-20T03:12:56.11+00:00","2021-04-09",{"id":155,"raw":156,"subject":59,"body_html":160,"body_text":161,"firm_name":162,"letter_id":163,"created_at":106,"fei_number":19,"letter_url":164,"updated_at":165,"action_type":22,"case_status":23,"posted_date":166,"marcs_cms_no":167,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":168,"body_fetched_at":169,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":166,"medical_device_id":19,"response_letter_date":19},3117,[157,158,159,58,59,13,13,13],"\u003Ctime datetime=\"2021-10-07T13:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-07T04:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-vapor-llc-dba-north-shore-vapor-618813-10072021\">J-Vapor LLC dba North Shore Vapor\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jamey J. Petruzzelli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>J-Vapor LLC dba North Shore Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>595 Broadway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Malden\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02148\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@northshorevapor.com\"> sales@northshorevapor.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:northshorevapor@gmail.com\"> northshorevapor@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jvaporinc@gmail.com\"> jvaporinc@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Jamey J. Petruzzelli:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.northshorevapor.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. &nbsp;Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. &nbsp;Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. &nbsp;These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.northshorevapor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Cereal Monster Frankn Berry 60mL and Icing on the Flake Strawberry 100mL.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. &nbsp;In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,300 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001204 on September 7, 2020. However, FDA issued a negative action for PMTA STN PM0001204 in the form of a Marketing Denial Order determination on August 31, 2021 which covers 1,509 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001204 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.&nbsp;\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. &nbsp;Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101639, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nVIA UPS and Electronic Mail\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>J-Vapor LLC dba North Shore Vapor Distribution\u003Cbr>\nNorth Shore Vapor Watertown LLC\u003Cbr>\nAttn: Jamey Petruzzelli, Registered Agent\u003Cbr>\n45 Lebanon Street\u003Cbr>\nMalden, MA 02148\u003C\u002Fp>\n\n\u003Cp>J-Vapor LLC dba North Shore Vapor Distribution\u003Cbr>\nAttn: Richard Lane Wise\u003Cbr>\n51 Washington Square North\u003Cbr>\nSalem, MA 01970\u003C\u002Fp>\n\n\u003Cp>North Shore Vapor Watertown LLC\u003Cbr>\n100 Main St\u003Cbr>\nWatertown, MA 02472-4416\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nnorthshorevapor.com@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com &nbsp;&nbsp;\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJamey J. Petruzzelli\n\nJ-Vapor LLC dba North Shore Vapor\n\n595 Broadway\n\nMalden, MA 02148\n\nUnited States\n\nsales@northshorevapor.com\n\nnorthshorevapor@gmail.com\n\njvaporinc@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Jamey J. Petruzzelli:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.northshorevapor.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.northshorevapor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Cereal Monster Frankn Berry 60mL and Icing on the Flake Strawberry 100mL.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,300 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001204 on September 7, 2020. However, FDA issued a negative action for PMTA STN PM0001204 in the form of a Marketing Denial Order determination on August 31, 2021 which covers 1,509 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001204 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101639, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nJ-Vapor LLC dba North Shore Vapor Distribution\n\nNorth Shore Vapor Watertown LLC\n\nAttn: Jamey Petruzzelli, Registered Agent\n\n45 Lebanon Street\n\nMalden, MA 02148\n\nJ-Vapor LLC dba North Shore Vapor Distribution\n\nAttn: Richard Lane Wise\n\n51 Washington Square North\n\nSalem, MA 01970\n\nNorth Shore Vapor Watertown LLC\n\n100 Main St\n\nWatertown, MA 02472-4416\n\nDomains By Proxy, LLC\n\nnorthshorevapor.com@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","J-Vapor LLC dba North Shore Vapor","j-vapor-llc-dba-north-shore-vapor-618813-10072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-vapor-llc-dba-north-shore-vapor-618813-10072021","2026-10-26T08:09:02.195358+00:00","2021-10-07","618813","Jamey J. Petruzzelli","2026-08-20T02:33:16.77+00:00",{"id":171,"raw":172,"subject":177,"body_html":178,"body_text":179,"firm_name":180,"letter_id":181,"created_at":127,"fei_number":19,"letter_url":182,"updated_at":183,"action_type":22,"case_status":23,"posted_date":184,"marcs_cms_no":185,"product_type":186,"closeout_date":19,"issuing_office":176,"recipient_name":187,"body_fetched_at":188,"delivery_method":189,"recipient_title":19,"reference_number":19,"action_taken_date":190,"medical_device_id":19,"response_letter_date":19},2127,[173,174,175,176,177,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-27T05:00:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022\">North American Diagnostics, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Elizabeth A. Lashinsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>618 Ridgewood Ave., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holly Hill\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32117\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ealash52@gmail.com\"> ealash52@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 643203\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDecember 27, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lashinsky:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong> Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70.\u003C\u002Fstrong> Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fstrong> Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80.\u003C\u002Fstrong> Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong> Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a).\u003C\u002Fstrong> Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong> Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b).\u003C\u002Fstrong> Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\u003Cbr>\n\u003Cbr>\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to\u003C\u002Fstrong> COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 643203\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nBlake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-%20emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nElizabeth A. Lashinsky\n\nRecipient Title\n\nOwner\n\nNorth American Diagnostics, LLC\n\n618 Ridgewood Ave., Suite 100\n\nHolly Hill, FL 32117\n\nUnited States\n\nealash52@gmail.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 643203\n\nDecember 27, 2022\n\nDear Ms. Lashinsky:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\n\nOur inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\n\nThis inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a). Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\n\n2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70. Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\n\n3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\n\n4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80. Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\n\n5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\n\n6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a). Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\n\n7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\n\n8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b). Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\n\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\n\nWe reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\n\nYour firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 643203 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n______________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","North American Diagnostics, LLC","north-american-diagnostics-llc-643203-12272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022","2026-10-26T08:09:34.512211+00:00","2023-04-18","643203","Medical Devices","Elizabeth A. Lashinsky","2026-08-20T01:09:41.813+00:00","VIA Electronic Mail","2022-12-27",{"id":192,"raw":193,"subject":198,"body_html":199,"body_text":200,"firm_name":201,"letter_id":202,"created_at":203,"fei_number":19,"letter_url":204,"updated_at":205,"action_type":22,"case_status":23,"posted_date":206,"marcs_cms_no":207,"product_type":208,"closeout_date":19,"issuing_office":197,"recipient_name":209,"body_fetched_at":210,"delivery_method":211,"recipient_title":19,"reference_number":212,"action_taken_date":213,"medical_device_id":19,"response_letter_date":19},22011,[194,195,196,197,198,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-22T04:00:00Z\">10\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-nuclear-medicine-llc-736893-10222026\">Northland Nuclear Medicine, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                          \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-08\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nathan J. Fleck, Pharm.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Northland Nuclear Medicine, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1815 Michigan Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bismarck\u003C\u002Fspan>, \u003Cspan>ND\u003C\u002Fspan> \u003Cspan>58504-6121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-08\u003C\u002Fp>\u003Cp>To Dr. Nathan J. Fleck:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Northland Nuclear Medicine, LLC, FDA Establishment Identifier (FEI) 3005334016, located at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your June 11, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations observed during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Investigation of Out-of-Limit Environmental Monitoring Results\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate out-of-limit (OOL) environmental monitoring (EM) results, identify the root cause of recurring microbial recoveries, and implement appropriate corrective actions. EM data from March 2024 through April 2026 revealed an adverse trend with over 100 microbial recoveries from ISO 5 areas (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> and laminar airflow workstation (LAFW)), including counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs). These recoveries were not formally identified, preventing your firm from conducting adequate investigations. More than 90 ISO 5 isolates were documented as “resembles previously identified \u003Cem>Bacillus\u003C\u002Fem> colonies” or “resembles previously identified colonies” in lieu of formal microbial identification, with no record of which previously identified organism the colony purportedly resembled. Since December 2024, of approximately 75 ISO 5 microbial recoveries, only two were sent for formal identification. No genus or species recovered in ISO 5 areas has been recorded in your EM log since September 2025. Operator training for interpreting \u003Cstrong>(b)(4)\u003C\u002Fstrong> plate results consisted of a single presentation slide instructing personnel to “count CFUs and record results,” with no instruction regarding microbial identification.\u003C\u002Fp>\u003Cp>Additionally, \u003Cstrong>(b)(4)\u003C\u002Fstrong> ISO 7 cleanroom certification results for areas surrounding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and LAFW revealed microbial recoveries that exceeded your action limits and were not adequately investigated. For example, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU active air recovery described as bacterial and yeast was not adequately identified because the sample plates were received with \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the lid. For a \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU recovery sent for identification, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were identified as \u003Cem>Pseudopithomyces palmicola\u003C\u002Fem> and the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were identified as \u003Cem>Micrococcus\u003C\u002Fem> spp. and coryneform bacillus. Investigations were not initiated. Further, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product review acknowledges “excess CFUs as an ongoing issue in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom.”\u003C\u002Fp>\u003Cp>Your firm systematically failed to adequately investigate out-of-limit environmental monitoring results, to identify root causes of recurring microbial contamination in critical ISO 5 areas, and to implement effective corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>In your response, you commit to ensuring that future microbial colony recoveries from ISO 5 areas will be properly identified and documented. Your response is inadequate because it does not include a retrospective assessment of the unidentified recoveries or an evaluation of adverse trends, does not assess the adequacy of past batch release decisions made in the absence of organism identification, and does not address the documented presence of spore-forming bacteria and fungi in your ISO-classified environments.\u003C\u002Fp>\u003Cp>Environmental isolate identification data provides essential information for an investigation into routes of contamination, such as when investigating an adverse environmental control trend, media fill contamination, or a product sterility testing failure. EM should include routine identification of microorganisms to the species (or, where appropriate, genus) level, including isolates recovered from an ISO 5 environment, its surrounding cleanroom, and personnel.\u003C\u002Fp>\u003Cp>It is essential that cleaning and disinfection procedures are described in sufficient detail, including the preparation, disinfectant selection, and contact time to enable reproducibility and ensure that potential contaminants are adequately removed from surfaces. The effectiveness of disinfection procedures should be evaluated through a routine EM program, and adverse trends should prompt reassessment of disinfectant selection, concentration, contact time, and application frequency.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Investigation and CAPA for Recurring Manufacturing Deficiencies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to conduct adequate effectiveness checks for CAPAs to prevent recurrence.\u003C\u002Fp>\u003Cp>Multiple CAPAs for recurring low \u003Cstrong>(b)(4)\u003C\u002Fstrong> yields were closed without your required effectiveness checks. Yields continued to fall below your established \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit. No investigations were initiated for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches manufactured between August 2024 and April 2025 that failed the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit, with yields as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Rather than identifying and correcting the root cause, you lowered the yield limit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Yields subsequently fell below your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit. Notably, Incident Report NNM 2025 08 states, “This has been an ongoing issue now for more than a year. We are continuing to evaluate the situation in an attempt to increase yields.” The effectiveness check for that incident was marked “No” with no additional corrective action identified. You continue to manufacture your PET drug without resolving the root cause of the low yields.\u003C\u002Fp>\u003Cp>PET drug producers must establish appropriate action limits for radiochemical yield and investigate and correct the root cause when those limits are exceeded. Low yields or a downward trend in yield are recognized indicators that the production process may be losing control. Lowering a yield limit to accommodate a failing process does not satisfy this requirement. Producers must maintain adequate production and process controls to ensure consistent production and must implement appropriate CAPA to prevent recurrence of nonconforming results.\u003C\u002Fp>\u003Cp>In your response, you commit to retrain manufacturing personnel on effectiveness check requirements and to formally complete the incident report form. Your response is inadequate because you have not conducted a retrospective evaluation of the batches manufactured and it fails to address the root cause of the persistent low-yield problem. Additionally, your response does not address the adequacy of lowering your yield limit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% as a corrective measure in lieu of identifying and resolving the root cause of persistent yield failures.\u003C\u002Fp>\u003Cp>To ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Training alone does not address the systemic failures that allowed deficient investigations to persist undetected by quality unit (QU) oversight.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\u003Cbr>o establishing appropriate limits,\u003Cbr>o sampling methods,\u003Cbr>o sampling locations and frequencies,\u003Cbr>o trend analysis,\u003Cbr>o appropriate investigation of deviations and adverse trends,\u003Cbr>o and a comprehensive CAPA plan based on the findings of the assessment.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\u003Cbr>o staff competencies (including use of appropriate subject matter experts)\u003Cbr>o written procedures\u003Cbr>o scientific rigor and foundation\u003Cbr>o scope determination\u003Cbr>o root cause evaluations\u003Cbr>o CAPA effectiveness\u003Cbr>o quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted.\u003Cbr>o and, based on above, detailed systemic improvements to the investigation system\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o a determination of whether procedures used by your firm are robust and\u003Cbr>o appropriate\u003Cbr>o provisions for QU oversight throughout your operations to evaluate\u003Cbr>o adherence to appropriate practices\u003Cbr>o a complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Control of Environmental Monitoring Plates\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately control your EM contact plates used to monitor your production operations.\u003C\u002Fp>\u003Cp>EM plates were stored inside a \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing a significant amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution before and after sampling. You failed to assess the impact of this practice on microbial recovery.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is a \u003Cstrong>(b)(4)\u003C\u002Fstrong> with well-documented sporicidal activity. Exposure of EM plates to \u003Cstrong>(b)(4)\u003C\u002Fstrong> can kill or suppress the microorganisms these tests are designed to recover, rendering results unreliable and potentially generating false negatives.\u003C\u002Fp>\u003Cp>In your response, you state that personnel have stopped spraying EM plates and that procedures have been updated accordingly. Your response is inadequate because it does not address the reliability of historical EM data collected using the compromised methodology, does not include a retrospective assessment of past EM results that were affected by \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure, and does not evaluate the adequacy of prior batch release decisions made in the absence of reliable environmental monitoring data.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Airflow Visualization Studies (Smoke Studies)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to ensure adequate control of airflow in the ISO 5 critical aseptic processing area. Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.\u003C\u002Fp>\u003Cp>Adequate contamination control in an aseptic PET drug manufacturing environment requires that monitoring tools, disinfection practices, and airflow qualification studies be designed and executed in a manner that meaningfully protects the sterility of the product. Compromised environmental monitoring media, inadequate airflow qualification, and failure to disinfect product-contact surfaces prior to aseptic operations collectively undermine the sterility assurance of your PET drugs.\u003C\u002Fp>\u003Cp>In your response, you commit to include transfer of starting components and materials prior to mock operations going forward. Your response is inadequate because you do not address the absence of a validated, dynamic evaluation of actual LAFW and \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations under representative conditions.\u003C\u002Fp>\u003Cp>\u003Cem>Failure to Adequately Disinfect \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately disinfect the exterior surfaces of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to aseptic manufacturing operations and failed to establish written procedures for the cleaning and disinfection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces.\u003C\u002Fp>\u003Cp>In your response, you indicate that personnel were informed and retrained on the procedures for proper disinfection. Your response is inadequate because it does not establish a written disinfection procedure for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a required step in your aseptic manufacturing process.\u003C\u002Fp>\u003Cp>PET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients. Cleaning and disinfection should be performed frequently to ensure consistent control of environmental quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\u003Cbr>o unique labeling of each sample\u003Cbr>o signatures of all staff who handle the sample\u003Cbr>o complete tracking of sample integrity and custody\u003Cbr>o date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\u003Cbr>o digital time-stamped photos of all plates\u003Cbr>o signatures of personnel performing reading of microbial counts\u003Cbr>o provisions for verifications and routine quality assurance oversight.\u003C\u002Fli>\u003Cli>Comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o all human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o facility layout\u003Cbr>o personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o disinfection practices and procedures\u003Cbr>o specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A thorough, independent evaluation of airflow unidirectionality in your aseptic process. Ensure smoke studies are conducted under dynamic conditions, with comprehensive evaluations of aseptic processing airflow unidirectionality, including the impact of aseptic interventions and surrounding cleanroom hazards. Conduct the smoke studies after you remediate your aseptic operation, using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a regulatory meeting held on December 13, 2023, FDA discussed similar CGMP violations. You proposed specific remediation for these violations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Guidance on PET Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>PET Drugs—Current Good Manufacturing Practice\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3005334016 and ATTN: Compliance officer Michael Klapal in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-08\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nNathan J. Fleck, Pharm.D.\n\nRecipient Title\n\nPresident & Owner\n\nNorthland Nuclear Medicine, LLC\n\n1815 Michigan Ave.\n\nBismarck, ND 58504-6121\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 22, 2026\nWARNING LETTER\nReference number: 320-27-08\nTo Dr. Nathan J. Fleck:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Northland Nuclear Medicine, LLC, FDA Establishment Identifier (FEI) 3005334016, located at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\nBecause your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your June 11, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations observed during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).\nInadequate Investigation of Out-of-Limit Environmental Monitoring Results\nYour firm failed to adequately investigate out-of-limit (OOL) environmental monitoring (EM) results, identify the root cause of recurring microbial recoveries, and implement appropriate corrective actions. EM data from March 2024 through April 2026 revealed an adverse trend with over 100 microbial recoveries from ISO 5 areas (e.g., (b)(4) and laminar airflow workstation (LAFW)), including counts of (b)(4) colony forming units (CFUs). These recoveries were not formally identified, preventing your firm from conducting adequate investigations. More than 90 ISO 5 isolates were documented as “resembles previously identified Bacillus colonies” or “resembles previously identified colonies” in lieu of formal microbial identification, with no record of which previously identified organism the colony purportedly resembled. Since December 2024, of approximately 75 ISO 5 microbial recoveries, only two were sent for formal identification. No genus or species recovered in ISO 5 areas has been recorded in your EM log since September 2025. Operator training for interpreting (b)(4) plate results consisted of a single presentation slide instructing personnel to “count CFUs and record results,” with no instruction regarding microbial identification.\nAdditionally, (b)(4) ISO 7 cleanroom certification results for areas surrounding your (b)(4) and LAFW revealed microbial recoveries that exceeded your action limits and were not adequately investigated. For example, a (b)(4) CFU active air recovery described as bacterial and yeast was not adequately identified because the sample plates were received with (b)(4) on the lid. For a (b)(4) CFU recovery sent for identification, (b)(4) CFU were identified as Pseudopithomyces palmicola and the remaining (b)(4) CFU were identified as Micrococcus spp. and coryneform bacillus. Investigations were not initiated. Further, your (b)(4) product review acknowledges “excess CFUs as an ongoing issue in the (b)(4) cleanroom.”\nYour firm systematically failed to adequately investigate out-of-limit environmental monitoring results, to identify root causes of recurring microbial contamination in critical ISO 5 areas, and to implement effective corrective action and preventive action (CAPA).\nIn your response, you commit to ensuring that future microbial colony recoveries from ISO 5 areas will be properly identified and documented. Your response is inadequate because it does not include a retrospective assessment of the unidentified recoveries or an evaluation of adverse trends, does not assess the adequacy of past batch release decisions made in the absence of organism identification, and does not address the documented presence of spore-forming bacteria and fungi in your ISO-classified environments.\nEnvironmental isolate identification data provides essential information for an investigation into routes of contamination, such as when investigating an adverse environmental control trend, media fill contamination, or a product sterility testing failure. EM should include routine identification of microorganisms to the species (or, where appropriate, genus) level, including isolates recovered from an ISO 5 environment, its surrounding cleanroom, and personnel.\nIt is essential that cleaning and disinfection procedures are described in sufficient detail, including the preparation, disinfectant selection, and contact time to enable reproducibility and ensure that potential contaminants are adequately removed from surfaces. The effectiveness of disinfection procedures should be evaluated through a routine EM program, and adverse trends should prompt reassessment of disinfectant selection, concentration, contact time, and application frequency.\nInadequate Investigation and CAPA for Recurring Manufacturing Deficiencies\nYou failed to conduct adequate effectiveness checks for CAPAs to prevent recurrence.\nMultiple CAPAs for recurring low (b)(4) yields were closed without your required effectiveness checks. Yields continued to fall below your established (b)(4)% limit. No investigations were initiated for approximately (b)(4) batches manufactured between August 2024 and April 2025 that failed the (b)(4)% limit, with yields as low as (b)(4)%. Rather than identifying and correcting the root cause, you lowered the yield limit from (b)(4)% to (b)(4)%. Yields subsequently fell below your revised (b)(4)% limit. Notably, Incident Report NNM 2025 08 states, “This has been an ongoing issue now for more than a year. We are continuing to evaluate the situation in an attempt to increase yields.” The effectiveness check for that incident was marked “No” with no additional corrective action identified. You continue to manufacture your PET drug without resolving the root cause of the low yields.\nPET drug producers must establish appropriate action limits for radiochemical yield and investigate and correct the root cause when those limits are exceeded. Low yields or a downward trend in yield are recognized indicators that the production process may be losing control. Lowering a yield limit to accommodate a failing process does not satisfy this requirement. Producers must maintain adequate production and process controls to ensure consistent production and must implement appropriate CAPA to prevent recurrence of nonconforming results.\nIn your response, you commit to retrain manufacturing personnel on effectiveness check requirements and to formally complete the incident report form. Your response is inadequate because you have not conducted a retrospective evaluation of the batches manufactured and it fails to address the root cause of the persistent low-yield problem. Additionally, your response does not address the adequacy of lowering your yield limit from (b)(4)% to (b)(4)% as a corrective measure in lieu of identifying and resolving the root cause of persistent yield failures.\nTo ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Training alone does not address the systemic failures that allowed deficient investigations to persist undetected by quality unit (QU) oversight.\nIn response to this letter, provide:\nAn independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\no establishing appropriate limits,\no sampling methods,\no sampling locations and frequencies,\no trend analysis,\no appropriate investigation of deviations and adverse trends,\no and a comprehensive CAPA plan based on the findings of the assessment.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\no staff competencies (including use of appropriate subject matter experts)\no written procedures\no scientific rigor and foundation\no scope determination\no root cause evaluations\no CAPA effectiveness\no quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted.\no and, based on above, detailed systemic improvements to the investigation system\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no a determination of whether procedures used by your firm are robust and\no appropriate\no provisions for QU oversight throughout your operations to evaluate\no adherence to appropriate practices\no a complete and final review of each batch and its related information before the QU disposition decision\no oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n2. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).\nInadequate Control of Environmental Monitoring Plates\nYou failed to adequately control your EM contact plates used to monitor your production operations.\nEM plates were stored inside a (b)(4) containing a significant amount of (b)(4) solution before and after sampling. You failed to assess the impact of this practice on microbial recovery.\n(b)(4) is a (b)(4) with well-documented sporicidal activity. Exposure of EM plates to (b)(4) can kill or suppress the microorganisms these tests are designed to recover, rendering results unreliable and potentially generating false negatives.\nIn your response, you state that personnel have stopped spraying EM plates and that procedures have been updated accordingly. Your response is inadequate because it does not address the reliability of historical EM data collected using the compromised methodology, does not include a retrospective assessment of past EM results that were affected by (b)(4) exposure, and does not evaluate the adequacy of prior batch release decisions made in the absence of reliable environmental monitoring data.\nInadequate Airflow Visualization Studies (Smoke Studies)\nYour firm failed to ensure adequate control of airflow in the ISO 5 critical aseptic processing area. Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or (b)(4) operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.\nAdequate contamination control in an aseptic PET drug manufacturing environment requires that monitoring tools, disinfection practices, and airflow qualification studies be designed and executed in a manner that meaningfully protects the sterility of the product. Compromised environmental monitoring media, inadequate airflow qualification, and failure to disinfect product-contact surfaces prior to aseptic operations collectively undermine the sterility assurance of your PET drugs.\nIn your response, you commit to include transfer of starting components and materials prior to mock operations going forward. Your response is inadequate because you do not address the absence of a validated, dynamic evaluation of actual LAFW and (b)(4) operations under representative conditions.\nFailure to Adequately Disinfect (b)(4)\nYou failed to adequately disinfect the exterior surfaces of the (b)(4) prior to aseptic manufacturing operations and failed to establish written procedures for the cleaning and disinfection of (b)(4) surfaces.\nIn your response, you indicate that personnel were informed and retrained on the procedures for proper disinfection. Your response is inadequate because it does not establish a written disinfection procedure for the (b)(4) as a required step in your aseptic manufacturing process.\nPET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients. Cleaning and disinfection should be performed frequently to ensure consistent control of environmental quality.\nIn response to this letter, provide:\nA comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\no unique labeling of each sample\no signatures of all staff who handle the sample\no complete tracking of sample integrity and custody\no date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\no digital time-stamped photos of all plates\no signatures of personnel performing reading of microbial counts\no provisions for verifications and routine quality assurance oversight.\nComprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no all human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no facility layout\no personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no disinfection practices and procedures\no specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA thorough, independent evaluation of airflow unidirectionality in your aseptic process. Ensure smoke studies are conducted under dynamic conditions, with comprehensive evaluations of aseptic processing airflow unidirectionality, including the impact of aseptic interventions and surrounding cleanroom hazards. Conduct the smoke studies after you remediate your aseptic operation, using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nRepeat Violations at Facility\nIn a regulatory meeting held on December 13, 2023, FDA discussed similar CGMP violations. You proposed specific remediation for these violations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nGuidance on PET Drugs\nSee FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3005334016 and ATTN: Compliance officer Michael Klapal in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Northland Nuclear Medicine, LLC","northland-nuclear-medicine-llc-736893-10222026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-nuclear-medicine-llc-736893-10222026","2026-11-17T01:02:03.701861+00:00","2026-10-27","736893","Drugs","Nathan J. Fleck, Pharm.D.","2026-11-03T01:02:46.643+00:00","VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-08","2026-10-22",{"id":215,"raw":216,"subject":221,"body_html":222,"body_text":223,"firm_name":224,"letter_id":225,"created_at":18,"fei_number":19,"letter_url":226,"updated_at":227,"action_type":22,"case_status":23,"posted_date":228,"marcs_cms_no":229,"product_type":26,"closeout_date":19,"issuing_office":220,"recipient_name":230,"body_fetched_at":231,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":232,"medical_device_id":19,"response_letter_date":19},2757,[217,218,219,220,221,13,13,13],"\u003Ctime datetime=\"2022-04-12T13:20:00Z\">04\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-24T04:00:00Z\">03\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnortheast-seafood-products-inc-621620-03242022\">Northeast Seafood Products, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations Division West 4","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Paul Packer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Northeast Seafood Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4555 Kingston St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denver\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80239-3016\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division West 4\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 24, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nBlair T. Joyce, Co-Owner\u002FVice-President\u003Cbr>\nScott M. Packer, Co-Owner\u002FTreasurer\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Ref: CMS Case #621620\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Messrs. Packer and Joyce:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your seafood processing facility located at 4555 Kingston St., Denver, Colorado, on September 21, 22 - 23, 27– 29, and October 14 and 19, 2021. The inspection was initiated as part of a multistate foodborne outbreak investigation of \u003Cem>Salmonella\u003C\u002Fem> Thompson (S. Thompson) illnesses linked to seafood. According to the Centers for Disease Control and Prevention (CDC), 116 people from 14 states were infected with the outbreak strain of S. Thompson. On October 8, 2021, your firm recalled certain types of fresh seafood processed at your facility and distributed from May 2021 to October 7, 2021, because they had the potential of being contaminated with \u003Cem>Salmonella\u003C\u002Fem>. CDC and FDA have determined, based upon the epidemiologic, laboratory, and traceback evidence, that fresh seafood processed at your facility was the source of this multistate S. Thompson outbreak.\u003C\u002Fp>\n\n\u003Cp>During our inspection we collected environmental samples (swabs) from various areas in your facility, including areas that are near food during processing operations. FDA laboratory analyses found the presence of the outbreak strain of S. Thompson, a human pathogen, in your facility. Additionally, FDA found serious violations of the Seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (CFR), Part 123 (21 CFR Part 123) and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish and fishery products adulterated with the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)]. Based on our inspectional results, including review of FDA’s environmental testing and your HACCP plan, we have determined that the blue fin tuna and other fresh seafood processed by your firm are adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance through links in FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA 483), Inspectional Observations. You provided responses to the inspection and sample findings via email on November 1, 9, 17, and 19, 2021, which included corrective actions taken by your firm. We have reviewed the documentation and continue to have serious concerns with your current sanitation and HACCP programs as further described in this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Salmonella\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Salmonella\u003C\u002Fem> species are not endemic to seafood; therefore, FDA expects zero or non-detectable levels of \u003Cem>Salmonella\u003C\u002Fem> in seafood regardless of whether it is intended to be cooked before consumption or it is ready-to-eat (RTE). \u003Cem>Salmonella\u003C\u002Fem> in seafood is the result of human or animal fecal contamination of the harvest waters and\u002For fecal contamination during post-harvest handling and processing. The contamination can also be exacerbated by temperature abuse. Raw RTE seafood must have appropriate controls from harvest to consumption. Symptoms of infection can range from gastroenteritis (e.g., diarrhea, fever, and stomach cramps) that is self-limiting (i.e., resolves without treatment), to chronic health problems and hospitalization with life-threating illness. Although all age groups are susceptible to \u003Cem>Salmonella\u003C\u002Fem> infections, young children, the elderly, and those with weakened immune systems are more likely to have severe infections. Many strains of \u003Cem>Salmonella \u003C\u002Fem>have a very low infective dose, making prevention critical.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis of the environmental sample 1159734, collected on September 22, 2021, during the production of your fresh fish that is intended to be eaten raw or cooked by the consumer, confirmed thirteen (13) of 132 environmental swabs were positive for S. Thompson. The positive swabs were collected from various non-food contact locations in close proximity to areas where fish are processed in your facility, including the production room floor near processing and packaging equipment, floor drains in the production room, the leg of a stainless-steel processing table, and the shelf of a stainless-steel processing table. When product is exposed to the environment, inadequate sanitation and poor employee practices may lead to product contamination with pathogens in the environment, like Salmonella. If the contaminated fish is consumed raw or without being cooked adequately to sufficiently kill the pathogen, then people who consume the contaminated product may become ill.\u003C\u002Fp>\n\n\u003Cp>The FDA conducted whole genome sequencing (WGS) analysis on the thirteen (13) \u003Cem>Salmonella\u003C\u002Fem> isolates obtained from environmental sample 1159734. The WGS analysis determined that the isolates derived from the environmental sample were a genomic match with each other and matched the clinical isolates from an outbreak that occurred in 2020 as well as the 2021 outbreak referenced above. We advised you of the WGS results via a conference call on October 7, 2021.\u003C\u002Fp>\n\n\u003Cp>Although no environmental samples were collected from your firm prior to 2021, the following evidence suggests the outbreak strain was present in your facility as early as 2020. As mentioned, the WGS analysis determined the isolates derived from environmental sample 1159734 were a genomic match to clinical isolates in the 2020 outbreak. In addition, this particular strain of S. Thompson has not been identified elsewhere in the WGS database. During the 2020 and 2021 outbreaks, the majority of illnesses involved Colorado residents with similar onset dates of June 2020 to September 2020, and May 2021 to September 2021, respectively. You solely distribute your seafood products within Colorado, and sushi was the suspect vehicle for the 2020 outbreak. Furthermore, the insanitary conditions observed during the current inspection, along with the environmental swabs positive for \u003Cem>Salmonella\u003C\u002Fem> collected in various areas of your processing facility, increase the likelihood that pathogens can spread to food-contact surfaces or directly to RTE fish.\u003C\u002Fp>\n\n\u003Cp>These positive \u003Cem>Salmonella\u003C\u002Fem> findings and the associated outbreaks indicate that your firm is neither achieving satisfactory control against the presence of \u003Cem>Salmonella\u003C\u002Fem> within your facility nor implementing effective methods and controls to eliminate this human pathogen and protect food and food-contact surfaces from contamination. You should perform a comprehensive root-cause analysis to identify potential sources and routes of contamination and implement adequate corrective actions based on your findings. A comprehensive root-cause analysis should evaluate all potential sources and explain the basis for their elimination, including actions such as reassessment of your environmental testing program, review of sanitation procedures and monitoring records, observing employee practices and monitoring procedures, and review of traffic patterns and equipment layout. The root-cause analysis and associated corrective actions should demonstrate that all sources and potential routes of contamination have been identified and corrected to ensure future product is not contaminated. If the likely source of contamination cannot be identified, then the root-cause analysis should thoroughly investigate and evaluate all potential sources and implemented controls. Your response to this warning letter should include your comprehensive root-cause analysis and corrections made based on the root-cause analysis that ensure your food is not adulterated by \u003Cem>Salmonella\u003C\u002Fem>. These corrective actions should be in addition to the corrective actions which were taken immediately after you were notified of these \u003Cem>Salmonella\u003C\u002Fem> findings and associated outbreaks.\u003C\u002Fp>\n\n\u003Cp>During the October 7, 2021, conference call, you voluntarily agreed to recall seafood processed and distributed by your firm from May 2021 through October 7, 2021. You issued a press release on October 8, 2021, notifying your customers and retail consumers of your recall. You also voluntarily ceased processing operations at your facility on October 7, 2021, to implement corrective actions to address the presence of S. Thompson in your facility. Further, you hired a consultant to revise your environmental monitoring program (EMP) and sanitation procedures. You stated the consultant would assist with a root-cause analysis for the presence of \u003Cem>Salmonella\u003C\u002Fem>; however, you have not provided any documentation regarding the root-cause analysis except your revised EMP and your swabbing results for \u003Cem>Salmonella\u003C\u002Fem>. Although your environmental swab results were negative for \u003Cem>Salmonella\u003C\u002Fem>, testing alone is not sufficient to demonstrate you have removed all sources and routes of a resident strain of S. Thompson from your facility.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your completed and planned corrective actions. Your revised EMP now includes increased \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabbing for \u003Cem>Salmonella\u003C\u002Fem> and pathogenic E. coli (EHEC\u002FpSTEC) in addition to, Listeria. You have not submitted supporting documentation demonstrating the implementation of the EMP, which was planned for November 15, 2021. We note that the sample results you submitted \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental samples collected on \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were taken prior to the resumption of your processing operations and do not reflect the implementation of your EMP. We also recommend the following regarding your revised EMP: ensure the test method used has been validated on environmental surfaces, include a list and\u002For map of sampling collection sites, and include additional details regarding results interpretation. You also provided a production room sanitation checklist. However, you have not provided completed sanitation monitoring records demonstrating that you have implemented your revised sanitation procedures.\u003C\u002Fp>\n\n\u003Cp>You have indicated that you did not resume operations at your facility until you completed facility repairs and conducted additional environmental swabbing. You should continue to implement the necessary controls and procedures to ensure foodborne pathogens do not contaminate your seafood food products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Seafood HACCP\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must monitor the conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with the current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR 123.11(b)(1)-(8), to comply with 21 CFR 123.11(b).\u003C\u002Fp>\n\n\u003Cp>However:\u003C\u002Fp>\n\n\u003Cp>A. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that cleaning and sanitizing of utensils and equipment was conducted in a manner that protected against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR 117.35(a). This is related to the condition and cleanliness of food-contact surfaces, 21 CFR 123.11(b)(2). Specifically,\u003C\u002Fp>\n\n\u003Cp>i. On 9\u002F22\u002F2021, an employee in the processing room was observed using a high pressurize hose to spray the bottom shelf of a stainless-steel table to remove scales and debris during production hours. Spray was observed to hit the floor and the table, creating back-splash; a swab (#98) from that shelf tested positive for \u003Cem>Salmonella\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>ii. On 9\u002F23\u002F2021, an employee in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room (\u003Cstrong>(b)(4)\u003C\u002Fstrong> room) was observed using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> high pressure hose to clean the floors with shellfish in the room; back-splash was observed contaminating the outside of the product packaging of product being stored on pallets in plastic containers or in cardboard\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes.\u003C\u002Fp>\n\n\u003Cp>iii. On 9\u002F27\u002F2021, during sanitation operations, an employee was observed using their gloved hand to remove water from the east floor drain under the processing sink in the processing room. The employee then proceeded to touch clean cutting boards and stainless-steel tables without washing hands and replacing gloves.\u003C\u002Fp>\n\n\u003Cp>iv. On 9\u002F27\u002F2021, during \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> high pressure hose was used to clean the floor, and back-splash was observed on the food contact surfaces of the black ice carts.\u003C\u002Fp>\n\n\u003Cp>v. On 9\u002F27\u002F2021, during \u003Cstrong>(b)(4)\u003C\u002Fstrong> shift, the concentration of a new sanitizer solution used to store in-use utensils was observed at 0 PPM.\u003C\u002Fp>\n\n\u003Cp>vi. On 9\u002F27\u002F2021, during \u003Cstrong>(b)(4)\u003C\u002Fstrong> shift, apparent fish remnants and scales were observed on cutting boards that were documented during the pre-operation and post-operation inspections on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitation Report” as “clean and sanitary” after \u003Cstrong>(b)(4)\u003C\u002Fstrong> shift sanitation activities were completed.\u003C\u002Fp>\n\n\u003Cp>vii. On 9\u002F28\u002F2021, an employee was observed to retrieve a black ice cart and move it to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room to place ice in the cart without cleaning and sanitizing it; swab # 126, positive for \u003Cem>Salmonella\u003C\u002Fem>, was collected from a black floor mat within an estimated six feet of where these carts were stored.\u003C\u002Fp>\n\n\u003Cp>B. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that food-contact surfaces are maintained to protect food from being contaminated by any source, including unlawful indirect food additives, as required by 21 CFR 117.40(a)(6). This is related to prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces, including utensils, gloves, and outer garments, 21 CFR 123.11(b)(3). On 9\u002F27\u002F2021, during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> shift, in the staging area, black ice carts were observed stacked on their sides and coming in contact with the floor and wheels of other carts, contaminating the inside of the carts (food contact surfaces).\u003C\u002Fp>\n\n\u003Cp>C. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that drip or condensate from fixtures, ducts and pipes does not contaminate food, as required by 21 CFR 117.20(b)(4). This is related to the protection of food, food packaging materials, and food contact surfaces from adulteration with condensate, 21 CFR 123.11(b)(5). On 9\u002F22\u002F2021, condensation was observed dripping from the evaporator in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room onto the food contact surface of large gray bins used to store fresh fin fish.\u003C\u002Fp>\n\n\u003Cp>D. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that all plant equipment and utensils used in manufacturing, processing, packing, or holding food are adequately maintained to protect against contamination, as required by 21 CFR 117.40(a)(1). This is related to condition and cleanliness of food contact surfaces, 21 CFR 123.11(b)(2).\u003C\u002Fp>\n\n\u003Cp>i. On 9\u002F22\u002F2021, both histamine and non-histamine cutting boards were observed to be worn and have deep cuts in plastic, making them more difficult to properly clean and sanitize.\u003C\u002Fp>\n\n\u003Cp>ii. On 9\u002F22\u002F2021, bins and carts used to store fresh fin fish and ice were observed to be worn, chipped and damaged, making them more difficult to properly clean and sanitize.\u003C\u002Fp>\n\n\u003Cp>2. Sanitation control records must document the monitoring and corrections prescribed by 21 CFR 123.11(b), and information must be entered at the time it is observed, to comply with 21 CFR 123.11 (c). However, your sanitation control records did not contain actual conditions, and observations were not entered at the times observed. Specifically:\u003C\u002Fp>\n\n\u003Cp>A. Your sanitation records titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitation Report,” completed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, indicated that all monitored areas of sanitation were “okay” when the above insanitary conditions were observed.\u003C\u002Fp>\n\n\u003Cp>B. On 9\u002F27\u002F2021, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> shift “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitation Report,” which had entry times of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was observed to be completed entirely after the shift, not while the observations were made, and did not list the actual conditions and corrective actions on the form.\u003C\u002Fp>\n\n\u003Cp>C. On 9\u002F28\u002F2021, the pre-operation inspection was completed approximately 30 minutes after production began around \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your November 9, 2021, response indicated that you are revising your sanitation program and implementing additional procedures and checklists addressing accurate completion of forms, sanitary operations for decanting raw fish and seafood, hand washing and glove use, and pre, mid-shift, and post operational checklists. You indicated that these procedures and checklists would be completed by November 15, 2021, and implemented once staff was trained. You have not provided supporting documentation demonstrating that your staff has been trained on the new procedures and checklists or that the procedures and checklist have been implemented.\u003C\u002Fp>\n\n\u003Cp>Your responses dated November 9 and 17, 2021, detail the corrective actions you have taken to address the positive sample results and inspectional observations. The corrective actions include hiring a food safety consultant to assess and revise your operation procedures and environmental monitoring program, eliminating the use of high pressure hoses in the facility, conducting \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> the production room floor, replacing worn and damaged equipment, retraining employees, instituting the use of new cleaning and sanitizing compounds, and revising traffic patterns and limiting access into your production areas. We will verify the adequacy of your implemented corrective actions during your next inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR 117, Subpart B)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not maintain your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required by 21 CFR 117.35(a). Specifically, on September 21, 2021, the following facility conditions were observed:\u003C\u002Fp>\n\n\u003Cp>A. The floor throughout the processing and staging area had cracks (0.1- 0.5 inches deep and 1 – 6 inches long), which were too numerous to count, and pits, too numerous to count. These areas can harbor microorganisms and make it difficult to ensure proper cleaning and sanitizing.\u003C\u002Fp>\n\n\u003Cp>B. The wall and floor junctions throughout the processing and storage areas were observed to be damaged and crumbling. These areas can harbor microorganisms and make it difficult to ensure proper cleaning and sanitizing.\u003C\u002Fp>\n\n\u003Cp>C. The floor drain in the processing room under the east side processing sink had an estimated 2 inches of standing water. A slow draining floor drain is an indication of improper cleaning frequency. In addition, standing water can harbor microorganisms.\u003C\u002Fp>\n\n\u003Cp>D. Freezers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>had significant build-up of ice on the ceiling, floors, and entryway. Ice buildup is an indication that the units are improperly working and can lead to temperature abuse.\u003C\u002Fp>\n\n\u003Cp>Your responses dated November 1, 9 and 17, 2021, detail the corrective actions you have taken to address the insanitary facility conditions observed during the inspection. You state that you have \u003Cstrong>(b)(4)\u003C\u002Fstrong> the production room floor, replaced worn and damaged equipment, removed the ice build-up in the freezer, and conducted a \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning. We will verify the adequacy of your implemented corrective actions during your next inspection.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we offer the following comment regarding your sanitation standard operating procedures (SSOPs). Your SSOP for “Production Pre-Operation” states that “before \u003Cstrong>(b)(4)\u003C\u002Fstrong> the supervisor or manager on duty will . . . [v]isually inspect the processing area and certify that it is clean, sanitized and ready for use.” It also provides that “Sanitizer dip solutions will be tested for proper strength and distributed to each workstation” and “will be changed as often as necessary to assure effectiveness.” Also, your SSOP for “Production Post-Operation Procedures” states that “At the end of \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . “[t]he supervisor or manager on duty will inspect the processing area to certify that it is clean and ready for use \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Any deficiencies will be addressed immediately and corrected.” However, the observations above indicate that these SSOPs were not properly implemented.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) business days of receipt of this letter of the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303)236-3094 or the email address provided if you have questions regarding this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDistrict Director, FDA Denver District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision West 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPaul Packer\n\nRecipient Title\n\nCo-Owner\u002FPresident\n\nNortheast Seafood Products, Inc.\n\n4555 Kingston St\n\nDenver, CO 80239-3016\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division West 4\n\nUnited States\n\nMarch 24, 2022\n\nWARNING LETTER\n\nBlair T. Joyce, Co-Owner\u002FVice-President\n\nScott M. Packer, Co-Owner\u002FTreasurer\n\nRef: CMS Case #621620\n\nDear Messrs. Packer and Joyce:\n\nThe United States Food and Drug Administration (FDA) inspected your seafood processing facility located at 4555 Kingston St., Denver, Colorado, on September 21, 22 - 23, 27– 29, and October 14 and 19, 2021. The inspection was initiated as part of a multistate foodborne outbreak investigation of Salmonella Thompson (S. Thompson) illnesses linked to seafood. According to the Centers for Disease Control and Prevention (CDC), 116 people from 14 states were infected with the outbreak strain of S. Thompson. On October 8, 2021, your firm recalled certain types of fresh seafood processed at your facility and distributed from May 2021 to October 7, 2021, because they had the potential of being contaminated with Salmonella. CDC and FDA have determined, based upon the epidemiologic, laboratory, and traceback evidence, that fresh seafood processed at your facility was the source of this multistate S. Thompson outbreak.\n\nDuring our inspection we collected environmental samples (swabs) from various areas in your facility, including areas that are near food during processing operations. FDA laboratory analyses found the presence of the outbreak strain of S. Thompson, a human pathogen, in your facility. Additionally, FDA found serious violations of the Seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (CFR), Part 123 (21 CFR Part 123) and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish and fishery products adulterated with the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)]. Based on our inspectional results, including review of FDA’s environmental testing and your HACCP plan, we have determined that the blue fin tuna and other fresh seafood processed by your firm are adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance through links in FDA’s home page at www.fda.gov.\n\nAt the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA 483), Inspectional Observations. You provided responses to the inspection and sample findings via email on November 1, 9, 17, and 19, 2021, which included corrective actions taken by your firm. We have reviewed the documentation and continue to have serious concerns with your current sanitation and HACCP programs as further described in this letter.\n\nSalmonella\n\nSalmonella species are not endemic to seafood; therefore, FDA expects zero or non-detectable levels of Salmonella in seafood regardless of whether it is intended to be cooked before consumption or it is ready-to-eat (RTE). Salmonella in seafood is the result of human or animal fecal contamination of the harvest waters and\u002For fecal contamination during post-harvest handling and processing. The contamination can also be exacerbated by temperature abuse. Raw RTE seafood must have appropriate controls from harvest to consumption. Symptoms of infection can range from gastroenteritis (e.g., diarrhea, fever, and stomach cramps) that is self-limiting (i.e., resolves without treatment), to chronic health problems and hospitalization with life-threating illness. Although all age groups are susceptible to Salmonella infections, young children, the elderly, and those with weakened immune systems are more likely to have severe infections. Many strains of Salmonella have a very low infective dose, making prevention critical.\n\nFDA laboratory analysis of the environmental sample 1159734, collected on September 22, 2021, during the production of your fresh fish that is intended to be eaten raw or cooked by the consumer, confirmed thirteen (13) of 132 environmental swabs were positive for S. Thompson. The positive swabs were collected from various non-food contact locations in close proximity to areas where fish are processed in your facility, including the production room floor near processing and packaging equipment, floor drains in the production room, the leg of a stainless-steel processing table, and the shelf of a stainless-steel processing table. When product is exposed to the environment, inadequate sanitation and poor employee practices may lead to product contamination with pathogens in the environment, like Salmonella. If the contaminated fish is consumed raw or without being cooked adequately to sufficiently kill the pathogen, then people who consume the contaminated product may become ill.\n\nThe FDA conducted whole genome sequencing (WGS) analysis on the thirteen (13) Salmonella isolates obtained from environmental sample 1159734. The WGS analysis determined that the isolates derived from the environmental sample were a genomic match with each other and matched the clinical isolates from an outbreak that occurred in 2020 as well as the 2021 outbreak referenced above. We advised you of the WGS results via a conference call on October 7, 2021.\n\nAlthough no environmental samples were collected from your firm prior to 2021, the following evidence suggests the outbreak strain was present in your facility as early as 2020. As mentioned, the WGS analysis determined the isolates derived from environmental sample 1159734 were a genomic match to clinical isolates in the 2020 outbreak. In addition, this particular strain of S. Thompson has not been identified elsewhere in the WGS database. During the 2020 and 2021 outbreaks, the majority of illnesses involved Colorado residents with similar onset dates of June 2020 to September 2020, and May 2021 to September 2021, respectively. You solely distribute your seafood products within Colorado, and sushi was the suspect vehicle for the 2020 outbreak. Furthermore, the insanitary conditions observed during the current inspection, along with the environmental swabs positive for Salmonella collected in various areas of your processing facility, increase the likelihood that pathogens can spread to food-contact surfaces or directly to RTE fish.\n\nThese positive Salmonella findings and the associated outbreaks indicate that your firm is neither achieving satisfactory control against the presence of Salmonella within your facility nor implementing effective methods and controls to eliminate this human pathogen and protect food and food-contact surfaces from contamination. You should perform a comprehensive root-cause analysis to identify potential sources and routes of contamination and implement adequate corrective actions based on your findings. A comprehensive root-cause analysis should evaluate all potential sources and explain the basis for their elimination, including actions such as reassessment of your environmental testing program, review of sanitation procedures and monitoring records, observing employee practices and monitoring procedures, and review of traffic patterns and equipment layout. The root-cause analysis and associated corrective actions should demonstrate that all sources and potential routes of contamination have been identified and corrected to ensure future product is not contaminated. If the likely source of contamination cannot be identified, then the root-cause analysis should thoroughly investigate and evaluate all potential sources and implemented controls. Your response to this warning letter should include your comprehensive root-cause analysis and corrections made based on the root-cause analysis that ensure your food is not adulterated by Salmonella. These corrective actions should be in addition to the corrective actions which were taken immediately after you were notified of these Salmonella findings and associated outbreaks.\n\nDuring the October 7, 2021, conference call, you voluntarily agreed to recall seafood processed and distributed by your firm from May 2021 through October 7, 2021. You issued a press release on October 8, 2021, notifying your customers and retail consumers of your recall. You also voluntarily ceased processing operations at your facility on October 7, 2021, to implement corrective actions to address the presence of S. Thompson in your facility. Further, you hired a consultant to revise your environmental monitoring program (EMP) and sanitation procedures. You stated the consultant would assist with a root-cause analysis for the presence of Salmonella; however, you have not provided any documentation regarding the root-cause analysis except your revised EMP and your swabbing results for Salmonella. Although your environmental swab results were negative for Salmonella, testing alone is not sufficient to demonstrate you have removed all sources and routes of a resident strain of S. Thompson from your facility.\n\nWe have reviewed your completed and planned corrective actions. Your revised EMP now includes increased (b)(4) swabbing for Salmonella and pathogenic E. coli (EHEC\u002FpSTEC) in addition to, Listeria. You have not submitted supporting documentation demonstrating the implementation of the EMP, which was planned for November 15, 2021. We note that the sample results you submitted (b)(4) environmental samples collected on (b)(4)) were taken prior to the resumption of your processing operations and do not reflect the implementation of your EMP. We also recommend the following regarding your revised EMP: ensure the test method used has been validated on environmental surfaces, include a list and\u002For map of sampling collection sites, and include additional details regarding results interpretation. You also provided a production room sanitation checklist. However, you have not provided completed sanitation monitoring records demonstrating that you have implemented your revised sanitation procedures.\n\nYou have indicated that you did not resume operations at your facility until you completed facility repairs and conducted additional environmental swabbing. You should continue to implement the necessary controls and procedures to ensure foodborne pathogens do not contaminate your seafood food products.\n\nSeafood HACCP\n\nYour significant deviations are as follows:\n\n1. You must monitor the conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with the current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR 123.11(b)(1)-(8), to comply with 21 CFR 123.11(b).\n\nHowever:\n\nA. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that cleaning and sanitizing of utensils and equipment was conducted in a manner that protected against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR 117.35(a). This is related to the condition and cleanliness of food-contact surfaces, 21 CFR 123.11(b)(2). Specifically,\n\ni. On 9\u002F22\u002F2021, an employee in the processing room was observed using a high pressurize hose to spray the bottom shelf of a stainless-steel table to remove scales and debris during production hours. Spray was observed to hit the floor and the table, creating back-splash; a swab (#98) from that shelf tested positive for Salmonella.\n\nii. On 9\u002F23\u002F2021, an employee in the (b)(4) room ((b)(4) room) was observed using the (b)(4) high pressure hose to clean the floors with shellfish in the room; back-splash was observed contaminating the outside of the product packaging of product being stored on pallets in plastic containers or in cardboard\u002F(b)(4) boxes.\n\niii. On 9\u002F27\u002F2021, during sanitation operations, an employee was observed using their gloved hand to remove water from the east floor drain under the processing sink in the processing room. The employee then proceeded to touch clean cutting boards and stainless-steel tables without washing hands and replacing gloves.\n\niv. On 9\u002F27\u002F2021, during (b)(4), a (b)(4) high pressure hose was used to clean the floor, and back-splash was observed on the food contact surfaces of the black ice carts.\n\nv. On 9\u002F27\u002F2021, during (b)(4) shift, the concentration of a new sanitizer solution used to store in-use utensils was observed at 0 PPM.\n\nvi. On 9\u002F27\u002F2021, during (b)(4) shift, apparent fish remnants and scales were observed on cutting boards that were documented during the pre-operation and post-operation inspections on the “(b)(4) Sanitation Report” as “clean and sanitary” after (b)(4) shift sanitation activities were completed.\n\nvii. On 9\u002F28\u002F2021, an employee was observed to retrieve a black ice cart and move it to the (b)(4) room to place ice in the cart without cleaning and sanitizing it; swab # 126, positive for Salmonella, was collected from a black floor mat within an estimated six feet of where these carts were stored.\n\nB. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that food-contact surfaces are maintained to protect food from being contaminated by any source, including unlawful indirect food additives, as required by 21 CFR 117.40(a)(6). This is related to prevention of cross-contamination from insanitary objects to food, food packaging material, and other food contact surfaces, including utensils, gloves, and outer garments, 21 CFR 123.11(b)(3). On 9\u002F27\u002F2021, during the (b)(4) shift, in the staging area, black ice carts were observed stacked on their sides and coming in contact with the floor and wheels of other carts, contaminating the inside of the carts (food contact surfaces).\n\nC. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that drip or condensate from fixtures, ducts and pipes does not contaminate food, as required by 21 CFR 117.20(b)(4). This is related to the protection of food, food packaging materials, and food contact surfaces from adulteration with condensate, 21 CFR 123.11(b)(5). On 9\u002F22\u002F2021, condensation was observed dripping from the evaporator in the (b)(4) room onto the food contact surface of large gray bins used to store fresh fin fish.\n\nD. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that all plant equipment and utensils used in manufacturing, processing, packing, or holding food are adequately maintained to protect against contamination, as required by 21 CFR 117.40(a)(1). This is related to condition and cleanliness of food contact surfaces, 21 CFR 123.11(b)(2).\n\ni. On 9\u002F22\u002F2021, both histamine and non-histamine cutting boards were observed to be worn and have deep cuts in plastic, making them more difficult to properly clean and sanitize.\n\nii. On 9\u002F22\u002F2021, bins and carts used to store fresh fin fish and ice were observed to be worn, chipped and damaged, making them more difficult to properly clean and sanitize.\n\n2. Sanitation control records must document the monitoring and corrections prescribed by 21 CFR 123.11(b), and information must be entered at the time it is observed, to comply with 21 CFR 123.11 (c). However, your sanitation control records did not contain actual conditions, and observations were not entered at the times observed. Specifically:\n\nA. Your sanitation records titled “(b)(4) Sanitation Report,” completed on (b)(4), and (b)(4), indicated that all monitored areas of sanitation were “okay” when the above insanitary conditions were observed.\n\nB. On 9\u002F27\u002F2021, the (b)(4) shift “(b)(4) Sanitation Report,” which had entry times of (b)(4) and (b)(4), was observed to be completed entirely after the shift, not while the observations were made, and did not list the actual conditions and corrective actions on the form.\n\nC. On 9\u002F28\u002F2021, the pre-operation inspection was completed approximately 30 minutes after production began around (b)(4).\n\nYour November 9, 2021, response indicated that you are revising your sanitation program and implementing additional procedures and checklists addressing accurate completion of forms, sanitary operations for decanting raw fish and seafood, hand washing and glove use, and pre, mid-shift, and post operational checklists. You indicated that these procedures and checklists would be completed by November 15, 2021, and implemented once staff was trained. You have not provided supporting documentation demonstrating that your staff has been trained on the new procedures and checklists or that the procedures and checklist have been implemented.\n\nYour responses dated November 9 and 17, 2021, detail the corrective actions you have taken to address the positive sample results and inspectional observations. The corrective actions include hiring a food safety consultant to assess and revise your operation procedures and environmental monitoring program, eliminating the use of high pressure hoses in the facility, conducting (b)(4) cleaning and sanitation, (b)(4) the production room floor, replacing worn and damaged equipment, retraining employees, instituting the use of new cleaning and sanitizing compounds, and revising traffic patterns and limiting access into your production areas. We will verify the adequacy of your implemented corrective actions during your next inspection.\n\nCurrent Good Manufacturing Practice (21 CFR 117, Subpart B)\n\nYou did not maintain your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required by 21 CFR 117.35(a). Specifically, on September 21, 2021, the following facility conditions were observed:\n\nA. The floor throughout the processing and staging area had cracks (0.1- 0.5 inches deep and 1 – 6 inches long), which were too numerous to count, and pits, too numerous to count. These areas can harbor microorganisms and make it difficult to ensure proper cleaning and sanitizing.\n\nB. The wall and floor junctions throughout the processing and storage areas were observed to be damaged and crumbling. These areas can harbor microorganisms and make it difficult to ensure proper cleaning and sanitizing.\n\nC. The floor drain in the processing room under the east side processing sink had an estimated 2 inches of standing water. A slow draining floor drain is an indication of improper cleaning frequency. In addition, standing water can harbor microorganisms.\n\nD. Freezers (b)(4) and (b)(4) had significant build-up of ice on the ceiling, floors, and entryway. Ice buildup is an indication that the units are improperly working and can lead to temperature abuse.\n\nYour responses dated November 1, 9 and 17, 2021, detail the corrective actions you have taken to address the insanitary facility conditions observed during the inspection. You state that you have (b)(4) the production room floor, replaced worn and damaged equipment, removed the ice build-up in the freezer, and conducted a (b)(4) cleaning. We will verify the adequacy of your implemented corrective actions during your next inspection.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nIn addition to the above violations, we offer the following comment regarding your sanitation standard operating procedures (SSOPs). Your SSOP for “Production Pre-Operation” states that “before (b)(4) the supervisor or manager on duty will . . . [v]isually inspect the processing area and certify that it is clean, sanitized and ready for use.” It also provides that “Sanitizer dip solutions will be tested for proper strength and distributed to each workstation” and “will be changed as often as necessary to assure effectiveness.” Also, your SSOP for “Production Post-Operation Procedures” states that “At the end of (b)(4) . . . “[t]he supervisor or manager on duty will inspect the processing area to certify that it is clean and ready for use (b)(4). Any deficiencies will be addressed immediately and corrected.” However, the observations above indicate that these SSOPs were not properly implemented.\n\nPlease notify this office in writing within fifteen (15) business days of receipt of this letter of the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\n\nPlease send your reply to the Food and Drug Administration, Attention: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303)236-3094 or the email address provided if you have questions regarding this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDistrict Director, FDA Denver District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nDivision West 4","Northeast Seafood Products, Inc.","northeast-seafood-products-inc-621620-03242022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnortheast-seafood-products-inc-621620-03242022","2026-10-26T08:09:34.775767+00:00","2022-04-12","621620","Paul Packer","2026-08-20T02:01:20.25+00:00","2022-03-24",{"id":234,"raw":235,"subject":59,"body_html":239,"body_text":240,"firm_name":241,"letter_id":242,"created_at":243,"fei_number":19,"letter_url":244,"updated_at":245,"action_type":22,"case_status":23,"posted_date":246,"marcs_cms_no":247,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":19,"body_fetched_at":248,"delivery_method":71,"recipient_title":19,"reference_number":249,"action_taken_date":250,"medical_device_id":19,"response_letter_date":19},963,[236,237,238,58,59,13,13,13],"\u003Ctime datetime=\"2025-04-15T04:00:00Z\">04\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-10T04:00:00Z\">04\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthwest-freedom-vape-llc-dba-northwest-freedom-vape-701658-04102025\">Northwest Freedom Vape LLC d\u002Fb\u002Fa Northwest Freedom Vape\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501132\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Northwest Freedom Vape LLC d\u002Fb\u002Fa Northwest Freedom Vape\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>732 Park Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lebanon\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97355\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 10, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Northwest Freedom Vape LLC d\u002Fb\u002Fa Northwest Freedom Vape manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Camp Leader.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501132, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501132\n\nProduct:\n\nTobacco\n\nRecipient:\n\nNorthwest Freedom Vape LLC d\u002Fb\u002Fa Northwest Freedom Vape\n\n732 Park Street\n\nLebanon, OR 97355\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 10, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Northwest Freedom Vape LLC d\u002Fb\u002Fa Northwest Freedom Vape manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Camp Leader.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501132, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Northwest Freedom Vape LLC d\u002Fb\u002Fa Northwest Freedom Vape","northwest-freedom-vape-llc-dba-northwest-freedom-vape-701658-04102025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthwest-freedom-vape-llc-dba-northwest-freedom-vape-701658-04102025","2026-10-26T08:09:34.959136+00:00","2025-04-15","701658","2026-08-19T16:53:01.398+00:00","ER2501132","2025-04-10",{"id":252,"raw":253,"subject":122,"body_html":258,"body_text":259,"firm_name":260,"letter_id":261,"created_at":106,"fei_number":19,"letter_url":262,"updated_at":263,"action_type":22,"case_status":23,"posted_date":264,"marcs_cms_no":265,"product_type":208,"closeout_date":19,"issuing_office":257,"recipient_name":266,"body_fetched_at":267,"delivery_method":268,"recipient_title":19,"reference_number":19,"action_taken_date":269,"medical_device_id":19,"response_letter_date":19},3352,[254,255,256,257,122,13,13,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-21T04:00:00Z\">04\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021\">North American Hirudin Biotech Products Inc.\u003C\u002Fa>","Office of Regulatory Affairs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zengxun An\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Hirudin Biotech Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2531 Broadway, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Everett\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Regulatory Affairs\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 21, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 613103\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. An:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hirudin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the http:\u002F\u002Fushirudin.com\u002F website:\u003Cbr>\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “Is hirudin a potential therapeutic agent for arthritis?”\u003C\u002Fp>\n\n\u003Cp>• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\u003Cbr>\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\u003Cbr>\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Hirudin Tablet:\u003Cbr>\n&nbsp; &nbsp; o [N]aturally lowers cholesterol content from your blood system.\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood.\u003Cbr>\n&nbsp; &nbsp; o [D]issolve the . . . cholesterol in your blood . . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Red 65\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fbuyred65.com\u002F:\u003Cbr>\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\u003C\u002Fp>\n\n\u003Cp>• “[N]aturally lowers cholesterol content from your blood system.”\u003C\u002Fp>\n\n\u003Cp>• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\u003Cbr>\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\u003C\u002Fp>\n\n\u003Cp>• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Red 65:\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\u003Cbr>\n&nbsp; &nbsp; o [D]issolve . . . cholesterol in your blood. . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\u003Cbr>\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\u003C\u002Fp>\n\n\u003Cp>• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nZengxun An\n\nRecipient Title\n\nPresident\n\nNorth American Hirudin Biotech Products Inc.\n\n2531 Broadway, Suite A\n\nEverett, WA 98201\n\nUnited States\n\nIssuing Office:\n\nOffice of Regulatory Affairs\n\nUnited States\n\nApril 21, 2021\n\nIn reply, refer to CMS 613103\n\nWARNING LETTER\n\nDear Mr. An:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nHirudin\n\nOn the http:\u002F\u002Fushirudin.com\u002F website:\n\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\n\n• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “Is hirudin a potential therapeutic agent for arthritis?”\n\n• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nOn the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\n\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\n\n• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\nOn the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\n\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Hirudin Tablet:\n\no [N]aturally lowers cholesterol content from your blood system.\n\no Blood-thinning . . . help normalize the blood sugar level in your blood.\n\no [D]issolve the . . . cholesterol in your blood . . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nRed 65\n\nOn the website http:\u002F\u002Fbuyred65.com\u002F:\n\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\n\n• “[N]aturally lowers cholesterol content from your blood system.”\n\n• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\n\n• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\n\nOn the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\n\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\n\n• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Red 65:\n\no Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\n\no [D]issolve . . . cholesterol in your blood. . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\n• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\n\nOn the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\n\nOn the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\n\n• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\n\nOn the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\n\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\n\n• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\n\n• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nYour “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","North American Hirudin Biotech Products Inc.","north-american-hirudin-biotech-products-inc-613103-04212021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021","2026-10-26T08:09:34.567247+00:00","2021-05-18","613103","Zengxun An","2026-08-20T03:08:12.347+00:00","Overnight Delivery","2021-04-21",{"id":271,"raw":272,"subject":276,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":127,"fei_number":19,"letter_url":281,"updated_at":282,"action_type":22,"case_status":23,"posted_date":283,"marcs_cms_no":284,"product_type":132,"closeout_date":19,"issuing_office":120,"recipient_name":285,"body_fetched_at":286,"delivery_method":287,"recipient_title":19,"reference_number":19,"action_taken_date":288,"medical_device_id":19,"response_letter_date":19},2014,[273,274,275,120,276,13,13,13],"\u003Ctime datetime=\"2023-07-05T14:00:00Z\">07\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-29T04:00:00Z\">06\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-carolina-hemp-exchange-llc-dba-nc-hemp-shoppe-649018-06292023\">North Carolina Hemp Exchange, LLC dba NC Hemp Shoppe\u003C\u002Fa>","Interstate Commerce\u002FFood\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Diane R. Becker\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>North Carolina Hemp Exchange, LLC dba NC Hemp Shoppe\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6030 Creedmoor Rd. Unit 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Raleigh\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27612-2327\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 649018\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Becker:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) reviewed your websites at the Internet addresses www.nchempshoppe.com and https:\u002F\u002Fwww.yelp.com\u002Fbiz\u002Fnc-hemp-shoppe-raleigh in December 2022 and June 2023, respectively, and have determined that you take orders there for various human products, which you represent as containing Delta-8 tetrahydrocannabinol (THC). FDA has determined that your Stoner Patch Delta-8 Gummies Watermelon 500mg, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003C\u002Fp>\n\n\u003Cp>FDA has observed a proliferation of products containing the cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children.\u003Cbr>\n\u003Cbr>\nSee https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.\u003C\u002Fp>\n\n\u003Cp>FDA is particularly concerned that your products are in forms (e.g., candy, cookies, and chips) that are appealing to children, that mimic well-known snack food brands by using similar brand names, logos, or pictures on packaging, and that consumers may confuse with traditional foods. Therefore, with these products there is a risk of unintended consumption of the Delta-8 THC ingredient by consumers. In June 2022, FDA warned consumers about the accidental ingestion by children of food products containing THC.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> As noted in the warning, the agency received over 125 adverse event reports from January 1, 2021, through May 31, 2022, related to children and adults who consumed edible products containing THC. Ten of the reports specifically mention the edible product to be a copycat of popular foods. Your Stoner Patch Delta-8 Gummies Watermelon 500 mg, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg products are all in forms that may be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your Stoner Patch Delta-8 Gummies Watermelon 500 mg, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg products are foods to which Delta-8 THC has been added. Furthermore, your Delta-8 THC Flamin Hot Cheetos and Stoneo Oreo Cookies Delta-8 THC products are labeled with a Nutrition Facts panel which are more likely to be confused for a genuine food product.\u003C\u002Fp>\n\n\u003Cp>As defined in section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act (21 U.S.C. 348(a)) and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in conventional food does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your Stoner Patch Delta-8 Gummies Watermelon, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg Delta-8 THC Extra Strength products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of FDA’s concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 649018” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unfair or Deceptive Marketing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, the FTC has reviewed the online marketing of the Delta-8 THC products referenced above. Section 5 of the FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. This prohibition includes practices that present unwarranted health or safety risks. Commission Policy Statement on Unfairness, 104 F.T.C. 1070, 1071 (1984) (appended to \u003Cem>Int’l&nbsp;\u003C\u002Fem>\u003Cem>Harvester Co.\u003C\u002Fem>, 104 F.T.C. 949 (1984)); \u003Cem>see also Philip Morris, Inc.\u003C\u002Fem>, 82 F.T.C. 16 (1973) (alleging that distribution of sample razor blades without protective packaging in home-delivered newspapers was a health and safety hazard, particularly to young children, that violated Section 5). Preventing practices that present unwarranted health and safety risks, particularly to children, is one of the Commission’s highest priorities. FTC Strategic Plan for Fiscal Years 2022-2026 at 5.\u003C\u002Fp>\n\n\u003Cp>As noted above, your various Delta-8 THC products have an appearance and form similar to conventional candies and snack foods often consumed by children. Your Stoner Patch Watermelon gummies are marketed in packaging resembling that for Sour Patch Kids Watermelon Bites, including the use of a yellow background with a pink border, the same style and color scheme for the product name “Stoner Patch” as is used for “Sour Patch” (with the first word in light green and the second word in orange, and both words superimposed on a black graphical element), and the depiction of pink and green wedge-shaped candies. Likewise, your Stoney Patch 500mg Delta-8 THC Gummies are marketed in packaging that resembles that for Sour Patch Kids candy, including the use of a bright yellow background with green graphical elements at the corners, the similar style and color scheme of the product name (“Stoner Patch” and “Sour Patch,” with the first word in green and the second in orange, and both words superimposed on a black graphical element), and the depiction of multiple brightly-colored kidshaped gummy candies. Your Stoneo Delta-8 THC Oreos and Delta-8 THC Flamin Hot Cheetos are marketed in packaging strongly resembling that for Nabisco Oreo Double Stuf chocolate cookies (using the same blue background, a red triangle in the upper lefthand corner reading “DABISCO” in the style of the Nabisco logo, and a depiction of a crème-filled chocolate sandwich cookie with a splash of milk), and Cheetos Crunchy Xxtra Flamin’ Hot Cheese Flavored Snacks (featuring the same black and orange color scheme, the Cheetos name and logo, and a similar depiction of flames at the top and bottom of the package), respectively.\u003C\u002Fp>\n\n\u003Cp>Imitating non-THC-containing food products often consumed by children through the use of advertising or labeling is misleading. FTC Policy Statement on Deception, 103 F.T.C. 174, 176 n.9 (1984) (appended to \u003Cem>Cliffdale Assocs., Inc\u003C\u002Fem>., 103 F.T.C. 110 (1984)) (the nature, appearance, or intended use of a product may create an impression in the mind of the consumer, and it is deceptive if this impression is false and not corrected by the seller); 15 U.S.C. §§ 52, 55(a)(1) (under Section 12 of the FTC Act, which prohibits false advertisements for foods and drugs, the Commission must consider any consequences that may result from the use of the product under customary or usual conditions).\u003C\u002Fp>\n\n\u003Cp>Children are at particular risk for mistakenly ingesting edible THC products imitating traditional foods because they are more likely to focus on similarities of product appearance and packaging, and less likely to notice or be able to comprehend labeling text. Ingesting edible cannabis products can result in serious health consequences in children.3 Given the significant number of adverse events reported in connection with ingestion of edible products containing THC, advertising and packaging your Delta-8 THC products in a manner that is likely to be particularly appealing to young children could present an unwarranted risk to health and safety.\u003C\u002Fp>\n\n\u003Cp>You must immediately cease marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to be appealing to young children. The FTC also strongly urges you to review all of your marketing and product packaging for similar edible THC products, and to take swift and appropriate steps to protect consumers, especially young children.\u003C\u002Fp>\n\n\u003Cp>With regard to the FTC-related issues described in this letter, please notify Christine DeLorme, attorney with the FTC’s Division of Advertising Practices, via electronic mail at cdelorme@ftc.gov with 15 working days of receipt of this letter of the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Ms. DeLorme at (202) 326-2095.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>FDA Warns Consumers About the Accidental Ingestion by Children of Food Products Containing THC (June 16, 2022) https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Falerts-advisories-safety-information\u002Ffda-warns-consumers-about-accidental-ingestion-children-food-products-containing-thc\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Marit Tweet et al., \u003Cem>Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021\u003C\u002Fem>, Pediatrics 2023;151(2): e2022057761.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDiane R. Becker\n\nNorth Carolina Hemp Exchange, LLC dba NC Hemp Shoppe\n\n6030 Creedmoor Rd. Unit 100\n\nRaleigh, NC 27612-2327\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 649018\n\nDear Ms. Becker:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) reviewed your websites at the Internet addresses www.nchempshoppe.com and https:\u002F\u002Fwww.yelp.com\u002Fbiz\u002Fnc-hemp-shoppe-raleigh in December 2022 and June 2023, respectively, and have determined that you take orders there for various human products, which you represent as containing Delta-8 tetrahydrocannabinol (THC). FDA has determined that your Stoner Patch Delta-8 Gummies Watermelon 500mg, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nFDA has observed a proliferation of products containing the cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children.\n\nSee https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.\n\nFDA is particularly concerned that your products are in forms (e.g., candy, cookies, and chips) that are appealing to children, that mimic well-known snack food brands by using similar brand names, logos, or pictures on packaging, and that consumers may confuse with traditional foods. Therefore, with these products there is a risk of unintended consumption of the Delta-8 THC ingredient by consumers. In June 2022, FDA warned consumers about the accidental ingestion by children of food products containing THC.1 As noted in the warning, the agency received over 125 adverse event reports from January 1, 2021, through May 31, 2022, related to children and adults who consumed edible products containing THC. Ten of the reports specifically mention the edible product to be a copycat of popular foods. Your Stoner Patch Delta-8 Gummies Watermelon 500 mg, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg products are all in forms that may be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children.\n\nAdulterated Human Foods\n\nAccording to your product labeling, your Stoner Patch Delta-8 Gummies Watermelon 500 mg, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg products are foods to which Delta-8 THC has been added. Furthermore, your Delta-8 THC Flamin Hot Cheetos and Stoneo Oreo Cookies Delta-8 THC products are labeled with a Nutrition Facts panel which are more likely to be confused for a genuine food product.\n\nAs defined in section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.2\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act (21 U.S.C. 348(a)) and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in conventional food does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your Stoner Patch Delta-8 Gummies Watermelon, Stoneo Oreo Cookies Delta-8 THC, Delta-8 THC Flamin Hot Cheetos, and Stoney Patch 500mg Delta-8 THC Extra Strength products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of FDA’s concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 649018” in the subject line of your email.\n\nUnfair or Deceptive Marketing\n\nIn addition, the FTC has reviewed the online marketing of the Delta-8 THC products referenced above. Section 5 of the FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. This prohibition includes practices that present unwarranted health or safety risks. Commission Policy Statement on Unfairness, 104 F.T.C. 1070, 1071 (1984) (appended to Int’l Harvester Co., 104 F.T.C. 949 (1984)); see also Philip Morris, Inc., 82 F.T.C. 16 (1973) (alleging that distribution of sample razor blades without protective packaging in home-delivered newspapers was a health and safety hazard, particularly to young children, that violated Section 5). Preventing practices that present unwarranted health and safety risks, particularly to children, is one of the Commission’s highest priorities. FTC Strategic Plan for Fiscal Years 2022-2026 at 5.\n\nAs noted above, your various Delta-8 THC products have an appearance and form similar to conventional candies and snack foods often consumed by children. Your Stoner Patch Watermelon gummies are marketed in packaging resembling that for Sour Patch Kids Watermelon Bites, including the use of a yellow background with a pink border, the same style and color scheme for the product name “Stoner Patch” as is used for “Sour Patch” (with the first word in light green and the second word in orange, and both words superimposed on a black graphical element), and the depiction of pink and green wedge-shaped candies. Likewise, your Stoney Patch 500mg Delta-8 THC Gummies are marketed in packaging that resembles that for Sour Patch Kids candy, including the use of a bright yellow background with green graphical elements at the corners, the similar style and color scheme of the product name (“Stoner Patch” and “Sour Patch,” with the first word in green and the second in orange, and both words superimposed on a black graphical element), and the depiction of multiple brightly-colored kidshaped gummy candies. Your Stoneo Delta-8 THC Oreos and Delta-8 THC Flamin Hot Cheetos are marketed in packaging strongly resembling that for Nabisco Oreo Double Stuf chocolate cookies (using the same blue background, a red triangle in the upper lefthand corner reading “DABISCO” in the style of the Nabisco logo, and a depiction of a crème-filled chocolate sandwich cookie with a splash of milk), and Cheetos Crunchy Xxtra Flamin’ Hot Cheese Flavored Snacks (featuring the same black and orange color scheme, the Cheetos name and logo, and a similar depiction of flames at the top and bottom of the package), respectively.\n\nImitating non-THC-containing food products often consumed by children through the use of advertising or labeling is misleading. FTC Policy Statement on Deception, 103 F.T.C. 174, 176 n.9 (1984) (appended to Cliffdale Assocs., Inc., 103 F.T.C. 110 (1984)) (the nature, appearance, or intended use of a product may create an impression in the mind of the consumer, and it is deceptive if this impression is false and not corrected by the seller); 15 U.S.C. §§ 52, 55(a)(1) (under Section 12 of the FTC Act, which prohibits false advertisements for foods and drugs, the Commission must consider any consequences that may result from the use of the product under customary or usual conditions).\n\nChildren are at particular risk for mistakenly ingesting edible THC products imitating traditional foods because they are more likely to focus on similarities of product appearance and packaging, and less likely to notice or be able to comprehend labeling text. Ingesting edible cannabis products can result in serious health consequences in children.3 Given the significant number of adverse events reported in connection with ingestion of edible products containing THC, advertising and packaging your Delta-8 THC products in a manner that is likely to be particularly appealing to young children could present an unwarranted risk to health and safety.\n\nYou must immediately cease marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to be appealing to young children. The FTC also strongly urges you to review all of your marketing and product packaging for similar edible THC products, and to take swift and appropriate steps to protect consumers, especially young children.\n\nWith regard to the FTC-related issues described in this letter, please notify Christine DeLorme, attorney with the FTC’s Division of Advertising Practices, via electronic mail at cdelorme@ftc.gov with 15 working days of receipt of this letter of the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Ms. DeLorme at (202) 326-2095.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n___________________________\n\n1 FDA Warns Consumers About the Accidental Ingestion by Children of Food Products Containing THC (June 16, 2022) https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Falerts-advisories-safety-information\u002Ffda-warns-consumers-about-accidental-ingestion-children-food-products-containing-thc\n\n2 Under section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\n\n3 See, e.g., Marit Tweet et al., Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021, Pediatrics 2023;151(2): e2022057761.","North Carolina Hemp Exchange, LLC dba NC Hemp Shoppe","north-carolina-hemp-exchange-llc-dba-nc-hemp-shoppe-649018-06292023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-carolina-hemp-exchange-llc-dba-nc-hemp-shoppe-649018-06292023","2026-10-26T08:09:34.603531+00:00","2023-07-05","649018","Diane R. Becker","2026-08-20T00:59:15.709+00:00","Via Overnight Delivery","2023-06-29",{"id":290,"raw":291,"subject":59,"body_html":295,"body_text":296,"firm_name":297,"letter_id":298,"created_at":86,"fei_number":19,"letter_url":299,"updated_at":300,"action_type":22,"case_status":23,"posted_date":301,"marcs_cms_no":302,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":19,"body_fetched_at":303,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":301,"medical_device_id":19,"response_letter_date":19},1617,[292,293,294,58,59,13,13,13],"\u003Ctime datetime=\"2024-02-08T20:00:00Z\">02\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-08T05:00:00Z\">02\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr-melton-enterprises-llc-dba-north-georgia-vapor-676124-02082024\">R. Melton Enterprises LLC dba North Georgia Vapor \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>R. Melton Enterprises LLC dba North Georgia Vapor \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>214 Atlanta Road Suite D\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cumming\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 8, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To Whom It May Concern,\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that R. Melton Enterprises LLC d\u002Fb\u002Fa North Georgia Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Peach.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2401011, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ele Ibarra-Pratt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nR. Melton Enterprises LLC dba North Georgia Vapor\n\n214 Atlanta Road Suite D\n\nCumming, GA 30040\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nFebruary 8, 2024\n\nWARNING LETTER\n\nTo Whom It May Concern,\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that R. Melton Enterprises LLC d\u002Fb\u002Fa North Georgia Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Peach.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2401011, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nEle Ibarra-Pratt\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","R. Melton Enterprises LLC dba North Georgia Vapor","r-melton-enterprises-llc-dba-north-georgia-vapor-676124-02082024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr-melton-enterprises-llc-dba-north-georgia-vapor-676124-02082024","2026-10-26T08:09:46.318292+00:00","2024-02-08","676124","2026-08-20T00:19:03.509+00:00",{"id":305,"raw":306,"subject":312,"body_html":313,"body_text":314,"firm_name":315,"letter_id":316,"created_at":86,"fei_number":19,"letter_url":317,"updated_at":318,"action_type":22,"case_status":23,"posted_date":319,"marcs_cms_no":320,"product_type":208,"closeout_date":19,"issuing_office":310,"recipient_name":321,"body_fetched_at":322,"delivery_method":189,"recipient_title":19,"reference_number":19,"action_taken_date":323,"medical_device_id":19,"response_letter_date":19},1511,[307,308,309,310,311,13,13,13],"\u003Ctime datetime=\"2024-04-23T04:00:00Z\">04\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-12T04:00:00Z\">04\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthern-va-compounders-pllc-dba-akina-pharmacy-671700-04122024\">Northern VA Compounders PLLC, dba Akina Pharmacy \u003C\u002Fa>","Office of Pharmaceutical Quality","Compounding Pharmacy\u002FAdulterated Drug Products ","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bassem W. Girgis\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Northern VA Compounders PLLC, dba Akina Pharmacy \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>23475 Rock Haven Way, Suite 105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sterling\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>20166-4444\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>WL # 671700&nbsp;\u003C\u002Fp>\u003Cp>4\u002F12\u002F2024&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Girgis:&nbsp;\u003C\u002Fp>\u003Cp>From November 7, 2022, to December 9, 2022, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Northern VA Compounders PLLC dba Akina Pharmacy, located at 23475 Rock Haven Way, Suite 105, Sterling, VA 20166. During the inspection, the investigators noted serious deficiencies in your practices for producing drug products, which put patients at risk.&nbsp;\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483, Inspectional Observations, to your firm on December 9, 2022. FDA acknowledges receipt of your facility’s response, dated January 20, 2023, as well as your subsequent correspondence. FDA also acknowledges that, on December 30, 2022, your facility initiated a voluntary recall of all lots of drug products intended or expected to be sterile, within expiry, that were produced using \u003Cstrong>(b)(4)\u003C\u002Fstrong> noted to be for “research use only”, due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\u003C\u002Fp>\u003Cp>1. Your firm used a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the purposes of product sterilization that was not appropriate for pharmaceutical use.\u003C\u002Fp>\u003Cp>2. Your firm failed to confirm that the quality of water was suitable for its intended use in the production of non-sterile drug products.\u003C\u002Fp>\u003Cp>3. Your ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> classified aseptic processing areas had difficult to clean, particle-generating, and visibly dirty equipment and surfaces.\u003C\u002Fp>\u003Cp>4. Foreign matter in the production area.\u003C\u002Fp>\u003Cp>5. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your firm’s responses to the Form FDA 483. We acknowledge that, on December 30, 2022, your facility initiated a voluntary recall of all lots of drug products intended or expected to be sterile, within expiry, that were produced using \u003Cstrong>(b)(4)\u003C\u002Fstrong> noted to be labeled as for “research use only”, due to a lack of sterility assurance.\u003C\u002Fp>\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot evaluate whether the following corrective actions described in your response appear to be adequate because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\u003Cp>1. Regarding your firm’s use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the purposes of product sterilization that was not appropriate for pharmaceutical use, we acknowledge your commitments and proposed corrective actions. However, you did not include adequate supporting documentation, such as specifications on the current \u003Cstrong>(b)(4)\u003C\u002Fstrong> being utilized and the certificate of analysis.\u003C\u002Fp>\u003Cp>2. Regarding your firm’s failure to confirm that the quality of water was suitable for its intended use in the production of non-sterile drug products, we acknowledge your statement that, “Akina has sourced pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> water for non-sterile compounding from an NABP accredited drug distributor.” However, you did not include adequate supporting documentation, such as purchase records and thecertificate of analysis.\u003C\u002Fp>\u003Cp>In addition, we note that your firm intends to wash glassware (before sterilization) with water from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. We acknowledge your statement that, “Akina has contracted with an EPA-certified contract laboratory to perform preventative-maintenance and testing on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.” We reviewed the testing results provided in your response, which appear to only note the water passes the potability test required by the EPA. It is unclear how your firm determined that this water is suitable for cleaning glassware utilized in sterile production. For example, we are unsure whether your firm has endotoxin controls in place for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Endotoxin control is critical for components used in sterile production, particularly those that are \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, which is not generally recognized as an effective method to reduce the level of endotoxins.\u003C\u002Fp>\u003Cp>3. Regarding your firm’s ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> classified aseptic processing areas having difficult to clean, particle-generating, and visibly dirty equipment and surfaces, we acknowledge your commitments as well as your documentation demonstrating that staff have been retrained. Your response noted that non-viable and viable particle sampling was performed as part of your June 25, 2023, certification; however we have not received that supporting documentation for review. In addition, your response references Attachment 4D, but it does not appear to have been included for our review.\u003C\u002Fp>\u003Cp>4. Regarding your firm’s failure to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area, we acknowledge your commitments and we have reviewed your unidirectional flow device certification report, dated January 3, 2023. However, you did not include adequate supporting documentation, such as a detailed description of what was performed during the smoke studies and\u002For videos of the smoke studies. In addition, your response did not include your latest unidirectional certification report for your ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> BSC located within your “Sterile Hazardous Buffer Room.”\u003C\u002Fp>\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.&nbsp;\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.&nbsp;\u003C\u002Fp>\u003Cp>Your written notification should refer to the \u003Cstrong>Warning Letter # 671700\u003C\u002Fstrong>. Please address your reply to: orapharm1_responses@fda.hhs.gov and Compliance Officer Juan Jimenez (Juan.Jimenez@fda.hhs.gov).&nbsp;\u003C\u002Fp>\u003Cp>Please identify your correspondence with \u003Cstrong>Northern VA Compounders PLLC, dba Akina Pharmacy FEI # 3012590153; WL 671700\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>Please provide acknowledgement of receipt of this communication.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Lisa Harlan&nbsp;&nbsp;\u003Cbr>Program Division Director&nbsp;&nbsp;\u003Cbr>Office of Pharmaceutical Quality Operations Division I\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBassem W. Girgis\n\nRecipient Title\n\nPresident\n\nNorthern VA Compounders PLLC, dba Akina Pharmacy\n\n23475 Rock Haven Way, Suite 105\n\nSterling, VA 20166-4444\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality\n\nUnited States\n\nWARNING LETTER\nWL # 671700\n4\u002F12\u002F2024\nDear Mr. Girgis:\nFrom November 7, 2022, to December 9, 2022, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Northern VA Compounders PLLC dba Akina Pharmacy, located at 23475 Rock Haven Way, Suite 105, Sterling, VA 20166. During the inspection, the investigators noted serious deficiencies in your practices for producing drug products, which put patients at risk.\nFDA issued a Form FDA 483, Inspectional Observations, to your firm on December 9, 2022. FDA acknowledges receipt of your facility’s response, dated January 20, 2023, as well as your subsequent correspondence. FDA also acknowledges that, on December 30, 2022, your facility initiated a voluntary recall of all lots of drug products intended or expected to be sterile, within expiry, that were produced using (b)(4) noted to be for “research use only”, due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\nA. Compounded Drug Products Under the FDCA\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\nB. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\n1. Your firm used a (b)(4) for the purposes of product sterilization that was not appropriate for pharmaceutical use.\n2. Your firm failed to confirm that the quality of water was suitable for its intended use in the production of non-sterile drug products.\n3. Your ISO (b)(4) classified aseptic processing areas had difficult to clean, particle-generating, and visibly dirty equipment and surfaces.\n4. Foreign matter in the production area.\n5. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO (b)(4) area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nC. Corrective Actions\nWe have reviewed your firm’s responses to the Form FDA 483. We acknowledge that, on December 30, 2022, your facility initiated a voluntary recall of all lots of drug products intended or expected to be sterile, within expiry, that were produced using (b)(4) noted to be labeled as for “research use only”, due to a lack of sterility assurance.\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot evaluate whether the following corrective actions described in your response appear to be adequate because you did not include sufficient information or supporting documentation:\n1. Regarding your firm’s use of a (b)(4) for the purposes of product sterilization that was not appropriate for pharmaceutical use, we acknowledge your commitments and proposed corrective actions. However, you did not include adequate supporting documentation, such as specifications on the current (b)(4) being utilized and the certificate of analysis.\n2. Regarding your firm’s failure to confirm that the quality of water was suitable for its intended use in the production of non-sterile drug products, we acknowledge your statement that, “Akina has sourced pharmaceutical grade (b)(4) water for non-sterile compounding from an NABP accredited drug distributor.” However, you did not include adequate supporting documentation, such as purchase records and thecertificate of analysis.\nIn addition, we note that your firm intends to wash glassware (before sterilization) with water from your (b)(4) water system. We acknowledge your statement that, “Akina has contracted with an EPA-certified contract laboratory to perform preventative-maintenance and testing on the (b)(4) system.” We reviewed the testing results provided in your response, which appear to only note the water passes the potability test required by the EPA. It is unclear how your firm determined that this water is suitable for cleaning glassware utilized in sterile production. For example, we are unsure whether your firm has endotoxin controls in place for your (b)(4) water system. Endotoxin control is critical for components used in sterile production, particularly those that are (b)(4) sterilized, which is not generally recognized as an effective method to reduce the level of endotoxins.\n3. Regarding your firm’s ISO (b)(4) classified aseptic processing areas having difficult to clean, particle-generating, and visibly dirty equipment and surfaces, we acknowledge your commitments as well as your documentation demonstrating that staff have been retrained. Your response noted that non-viable and viable particle sampling was performed as part of your June 25, 2023, certification; however we have not received that supporting documentation for review. In addition, your response references Attachment 4D, but it does not appear to have been included for our review.\n4. Regarding your firm’s failure to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO (b)(4) area, we acknowledge your commitments and we have reviewed your unidirectional flow device certification report, dated January 3, 2023. However, you did not include adequate supporting documentation, such as a detailed description of what was performed during the smoke studies and\u002For videos of the smoke studies. In addition, your response did not include your latest unidirectional certification report for your ISO (b)(4) BSC located within your “Sterile Hazardous Buffer Room.”\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nYour written notification should refer to the Warning Letter # 671700. Please address your reply to: orapharm1_responses@fda.hhs.gov and Compliance Officer Juan Jimenez (Juan.Jimenez@fda.hhs.gov).\nPlease identify your correspondence with Northern VA Compounders PLLC, dba Akina Pharmacy FEI # 3012590153; WL 671700\nPlease provide acknowledgement of receipt of this communication.\nSincerely,\n\u002FS\u002F\nLisa Harlan\nProgram Division Director\nOffice of Pharmaceutical Quality Operations Division I","Northern VA Compounders PLLC, dba Akina Pharmacy","northern-va-compounders-pllc-dba-akina-pharmacy-671700-04122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthern-va-compounders-pllc-dba-akina-pharmacy-671700-04122024","2026-10-26T08:09:34.818987+00:00","2024-04-23","671700","Bassem W. Girgis","2026-08-20T00:09:59.658+00:00","2024-04-12",{"id":325,"raw":326,"subject":312,"body_html":332,"body_text":333,"firm_name":334,"letter_id":335,"created_at":127,"fei_number":19,"letter_url":336,"updated_at":337,"action_type":22,"case_status":338,"posted_date":339,"marcs_cms_no":340,"product_type":208,"closeout_date":341,"issuing_office":342,"recipient_name":343,"body_fetched_at":344,"delivery_method":189,"recipient_title":19,"reference_number":19,"action_taken_date":345,"medical_device_id":19,"response_letter_date":19},2238,[327,328,329,330,312,13,331,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-18T05:00:00Z\">11\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022\">North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-01272026\">\u003Ctime datetime=\"2026-03-20T04:00:00Z\">03\u002F20\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Justin K. Graves\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1736 North Greenville Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richardson\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75081-1808\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 11\u002F18\u002F2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case #: 642792\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Graves,\u003C\u002Fp>\n\n\u003Cp>From March 1, 2022, to March 10, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, located at 1736 North Greenville Avenue, Richardson, TX 75081. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on March 10, 2022. FDA acknowledges receipt of your facility’s response, dated March 30, 2022, as well as your subsequent correspondence. FDA acknowledges that your firm initiated a voluntary recall of drug products that are intended to be sterile on April 5, 2022. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA [21 U.S.C. § 353a] describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\n\u003Cbr>\n\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your firm used a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the purposes of product sterilization that was not appropriate for pharmaceutical use and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing was inadequate. Therefore, you do not have assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was integral throughout use.\u003C\u002Fp>\n\n\u003Cp>2. Your firm did not adequately disinfect materials or supplies during transfer from the ISO 8 cleanroom into higher classification areas.\u003C\u002Fp>\n\n\u003Cp>3. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>5. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. Regarding your response related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. In your response to Observation 1 of the Form FDA 483, we acknowledge your firm’s statement that you have regained supply of and resumed use of previously unavailable \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “immediate use sterile subcutaneous injectable compounding” at your facility. However, you did not provide sufficient evidence of the corrective actions, such as purchase orders, current batch records (i.e., formula work sheets), or \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedures for the newly acquired \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. Regarding the pink residue on the ceiling, vents, and walls in your production area as described in Observation 5 of the Form FDA 483, you provided your revised SOP, 02-CPCP-12 \u003Cem>Non-Sterile Hazardous Compound – Hormone Only&nbsp;\u003C\u002Fem>and committed to “attempting a deep scrubbing of the room.” It is unclear if this cleaning was attempted and\u002For effective to remediate this observation or if your revised procedures have prevented reoccurrence.\u003C\u002Fp>\n\n\u003Cp>3. In your response to Observation 7 of the Form FDA 483, we acknowledge your firm’s statement that, “Moving forward, when smoke studies are conducted, footage from video will record, in detail, the dynamic compounding of sterile compounding in a PEC.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such as an updated smoke study protocol or an updated detailed report, and\u002For video.\u003C\u002Fp>\n\n\u003Cp>4. In your response to Observation 8 of the Form FDA 483, we acknowledge your firm’s statement that, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such updated media fill protocol or results.\u003C\u002Fp>\n\n\u003Cp>In addition, from review of the evidence collected during the inspection, your October 26, 2021, \u003Cem>Environmental Monitoring Report\u003C\u002Fem> lists your action level for the ISO 5 area as&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fm\u003Csup>3\u003C\u002Fsup> for “Air Test” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fplate for “Surface Test.” Please note that any microbial contamination in the ISO 5 area is a serious concern and considered an insanitary condition. If any ISO 5 recovery occurs, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could have been affected.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case number 642792.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Shawn Larson, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov and Shawn.Larson@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Dr. Larson via phone at 214-253-5216 or email at Shawn.Larson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Justin K. Graves\n\nRecipient Title\n\nVice President\n\nNorth American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\n\n1736 North Greenville Avenue\n\nRichardson, TX 75081-1808\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 11\u002F18\u002F2022\n\nCase #: 642792\n\nWARNING LETTER\n\nDear Mr. Graves,\n\nFrom March 1, 2022, to March 10, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, located at 1736 North Greenville Avenue, Richardson, TX 75081. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on March 10, 2022. FDA acknowledges receipt of your facility’s response, dated March 30, 2022, as well as your subsequent correspondence. FDA acknowledges that your firm initiated a voluntary recall of drug products that are intended to be sterile on April 5, 2022. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA [21 U.S.C. § 353a] describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n\n1. Your firm used a (b)(4) for the purposes of product sterilization that was not appropriate for pharmaceutical use and the (b)(4) testing was inadequate. Therefore, you do not have assurance that the (b)(4) was integral throughout use.\n\n2. Your firm did not adequately disinfect materials or supplies during transfer from the ISO 8 cleanroom into higher classification areas.\n\n3. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\n4. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n\n5. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. Regarding your response related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\n1. In your response to Observation 1 of the Form FDA 483, we acknowledge your firm’s statement that you have regained supply of and resumed use of previously unavailable (b)(4) for “immediate use sterile subcutaneous injectable compounding” at your facility. However, you did not provide sufficient evidence of the corrective actions, such as purchase orders, current batch records (i.e., formula work sheets), or (b)(4) testing procedures for the newly acquired (b)(4).\n\n2. Regarding the pink residue on the ceiling, vents, and walls in your production area as described in Observation 5 of the Form FDA 483, you provided your revised SOP, 02-CPCP-12 Non-Sterile Hazardous Compound – Hormone Only and committed to “attempting a deep scrubbing of the room.” It is unclear if this cleaning was attempted and\u002For effective to remediate this observation or if your revised procedures have prevented reoccurrence.\n\n3. In your response to Observation 7 of the Form FDA 483, we acknowledge your firm’s statement that, “Moving forward, when smoke studies are conducted, footage from video will record, in detail, the dynamic compounding of sterile compounding in a PEC.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such as an updated smoke study protocol or an updated detailed report, and\u002For video.\n\n4. In your response to Observation 8 of the Form FDA 483, we acknowledge your firm’s statement that, “(b)(4).” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such updated media fill protocol or results.\n\nIn addition, from review of the evidence collected during the inspection, your October 26, 2021, Environmental Monitoring Report lists your action level for the ISO 5 area as (b)(4) cfu\u002Fm3 for “Air Test” and (b)(4) cfu\u002Fplate for “Surface Test.” Please note that any microbial contamination in the ISO 5 area is a serious concern and considered an insanitary condition. If any ISO 5 recovery occurs, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could have been affected.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\n\nYour written notification should refer to case number 642792.\n\nPlease electronically submit your reply, on company letterhead, to Shawn Larson, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov and Shawn.Larson@fda.hhs.gov\n\nIf you have questions regarding the contents of this letter, you may contact Dr. Larson via phone at 214-253-5216 or email at Shawn.Larson@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n__________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.","North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding","north-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022","2026-10-26T08:09:34.465242+00:00","Closed Out","2023-01-24","642792","2026-03-20","Division of Pharmaceutical Quality Operations II","Mr. Justin K. Graves","2026-08-20T01:18:42.458+00:00","2022-11-18",{"id":347,"raw":348,"subject":353,"body_html":354,"body_text":355,"firm_name":356,"letter_id":357,"created_at":86,"fei_number":19,"letter_url":358,"updated_at":359,"action_type":22,"case_status":23,"posted_date":360,"marcs_cms_no":19,"product_type":208,"closeout_date":19,"issuing_office":361,"recipient_name":362,"body_fetched_at":363,"delivery_method":364,"recipient_title":19,"reference_number":19,"action_taken_date":365,"medical_device_id":19,"response_letter_date":19},1837,[349,350,351,352,353,13,13,13],"\u003Ctime datetime=\"2023-09-19T13:20:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-01T04:00:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national\">Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maria S. LeMay-Bey, Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Isaiah Orton-Bey, Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16136 W. 7 Mile Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Detroit\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48235\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Moorherbs13@gmail.com\"> Moorherbs13@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS Case #655674\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 1, 2023\u003Cbr>\n\u003Cbr>\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) and FDA regulations. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache &amp; Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs &amp; Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>\u003Cbr>\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\u003Cbr>\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\u003Cbr>\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Anti-Viral”\u003C\u002Fu>\u003Cbr>\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Anti-Viral”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Appendix Support”\u003C\u002Fu>\u003Cbr>\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\u003C\u002Fu>\u003Cbr>\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Blood Pressure Normalizer”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\u003Cbr>\n• “It is a strong anti bacterial agent...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Brain Tune-Up”\u003C\u002Fu>\u003Cbr>\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\u003Cbr>\n• “Protects the brain from damage”\u003Cbr>\n• “Alleviates stress, anxiety, and depression”\u003Cbr>\n• “Improves memory and mood in Alzheimer’s patients”\u003Cbr>\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\u003Cbr>\n• “Can Help Fight Inflammation.”\u003Cbr>\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\u003Cbr>\n• “Can Reduce Anxiety.”\u003Cbr>\n• “Can Treat Depression.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Cardiovascular System”\u003C\u002Fu>\u003Cbr>\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Headache &amp; Pain Relief”\u003C\u002Fu>\u003Cbr>\nOn the “Headache &amp; Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Headache &amp; Pain Relief”\u003Cbr>\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Healthy Mommy Healthy Baby”\u003C\u002Fu>\u003Cbr>\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Quit Smoking”\u003C\u002Fu>\u003Cbr>\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Quit Smoking”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HyperThyroidism” (also referred to as “HyperThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\u003Cbr>\n• “For an overactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HypoThyroidism” (also referred to as “HypoThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\u003Cbr>\n• “For an underactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Mucus Release”\u003C\u002Fu>\u003Cbr>\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Parasite Cleanse”\u003C\u002Fu>\u003Cbr>\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Parasite Cleanse”\u003Cbr>\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“ResErection Extra Strength w\u002F Yohimbe Bark”\u003C\u002Fu>\u003Cbr>\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Tumor Release” (also referred to as “Tumor &amp; Cyst Support”)\u003C\u002Fu>\u003Cbr>\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Tumor Release” or “Tumor &amp; Cyst Support”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\u003Cbr>\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Un-Vax”\u003C\u002Fu>\u003Cbr>\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Venereal Defense”\u003C\u002Fu>\u003Cbr>\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Venereal Defense”\u003Cbr>\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\u003C\u002Fu>\u003Cbr>\nOn the “Womb Care Cramp Relief &amp; Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Womb Care Cramp Relief &amp; Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\u003Cbr>\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\u003Cbr>\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Lungs &amp; Respiratory”\u003C\u002Fu>\u003Cbr>\nOn the “Lungs &amp; Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003C\u002Fp>\n\n\u003Cp>• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)].\u003C\u002Fp>\n\n\u003Cp>With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&amp;C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>b. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>c. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>We note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\u003C\u002Fp>\n\n\u003Cp>You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and “Lungs &amp; Respiratory” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\u003Cbr>\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\u003Cbr>\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\u003Cbr>\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\u003Cbr>\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for weighing or measuring each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the weight or measure of each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for adding the component to the batch; and\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the addition of components to the batch;\u003Cbr>\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\u003Cbr>\n&nbsp; &nbsp; o The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\u003Cbr>\n&nbsp; &nbsp; o An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\u003Cbr>\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\u003Cbr>\n&nbsp; &nbsp; o Reviewed the batch production record [21 CFR 111.260(l)(1), including:\u003Cbr>\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\u003Cbr>\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\u003Cbr>\n&nbsp; &nbsp; o Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\u003Cbr>\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\u003Cbr>\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\u003C\u002Fp>\n\n\u003Cp>Once have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\u003C\u002Fp>\n\n\u003Cp>Specifically, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache &amp; Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\u003C\u002Fp>\n\n\u003Cp>2. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\u003Cbr>\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\u003Cbr>\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\u003Cbr>\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\u003C\u002Fp>\n\n\u003Cp>3. Your Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>,, “Headache &amp; Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\u003C\u002Fp>\n\n\u003Cp>4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache &amp; Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\u003Cbr>\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\u003Cbr>\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\u003Cbr>\n• The Headache &amp; Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\u003C\u002Fp>\n\n\u003Cp>5. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We offer the following additional comments:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMaria S. LeMay-Bey, Owner\n\nRecipient Title\n\nIsaiah Orton-Bey, Owner\n\nMoorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\n\n16136 W. 7 Mile Road\n\nDetroit, MI 48235\n\nUnited States\n\nMoorherbs13@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nCMS Case #655674\n\nAugust 1, 2023\n\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and FDA regulations. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache & Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs & Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\n\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\n\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\n\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\n\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\n\n“Anti-Viral”\n\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Anti-Viral”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\n\n“Appendix Support”\n\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\n\n“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\n\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Blood Pressure Normalizer”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\n\n• “It is a strong anti bacterial agent...”\n\n“Brain Tune-Up”\n\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\n\n• “Protects the brain from damage”\n\n• “Alleviates stress, anxiety, and depression”\n\n• “Improves memory and mood in Alzheimer’s patients”\n\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\n\n• “Can Help Fight Inflammation.”\n\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\n\n• “Can Reduce Anxiety.”\n\n• “Can Treat Depression.”\n\n“Cardiovascular System”\n\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\n\n“Headache & Pain Relief”\n\nOn the “Headache & Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Headache & Pain Relief”\n\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\n\n“Healthy Mommy Healthy Baby”\n\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\n\n“Quit Smoking”\n\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Quit Smoking”\n\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\n\n“HyperThyroidism” (also referred to as “HyperThyroid Support”)\n\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\n\n• “For an overactive Thyroid”\n\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\n\n“HypoThyroidism” (also referred to as “HypoThyroid Support”)\n\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\n\n• “For an underactive Thyroid”\n\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\n\n“Mucus Release”\n\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\n\n“Parasite Cleanse”\n\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Parasite Cleanse”\n\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\n\n“ResErection Extra Strength w\u002F Yohimbe Bark”\n\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\n\n“Tumor Release” (also referred to as “Tumor & Cyst Support”)\n\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Tumor Release” or “Tumor & Cyst Support”\n\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\n\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\n\n“Un-Vax”\n\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\n\n“Venereal Defense”\n\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Venereal Defense”\n\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\n\n“Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\n\nOn the “Womb Care Cramp Relief & Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Womb Care Cramp Relief & Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\n\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\n\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\n\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\n\n“Lungs & Respiratory”\n\nOn the “Lungs & Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. 321(p)].\n\nWith certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nThe dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\n\n1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nb. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nc. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nWe note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\n\nYou must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\n\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on (b)(4) with lot #(b)(4), “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on (b)(4) with lot #(b)(4), and “Lungs & Respiratory” manufactured on (b)(4) with lot #(b)(4), were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\n\n• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\n\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\n\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\n\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\n\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\n\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\n\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\n\n The initials of the person responsible for weighing or measuring each component used in the batch;\n\n The initials of the person responsible for verifying the weight or measure of each component used in the batch;\n\n The initials of the person responsible for adding the component to the batch; and\n\n The initials of the person responsible for verifying the addition of components to the batch;\n\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\n\no The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\n\no An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\n\no The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\n\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\n\no Reviewed the batch production record [21 CFR 111.260(l)(1), including:\n\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\n\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\n\no Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\n\no Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\n\no Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\n\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\n\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\n\nWe have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\n\nOnce have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\n\nSpecifically, on (b)(4), during the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the (b)(4) plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nMisbranded Dietary Supplements\n\nIn addition, your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache & Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache & Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\n\n2. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\n\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\n\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\n\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\n\n3. Your Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”),, “Headache & Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\n\n4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache & Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\n\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\n\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\n\n• The Headache & Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\n\n5. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nWe offer the following additional comments:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\n\nYour response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast Division 6","Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.","moorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-10-26T08:09:27.900006+00:00","2023-09-19","Division of Human and Animal Food Operations East VI","Maria S. LeMay-Bey, Owner","2026-08-20T00:39:30.007+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-08-01",18,{"510k":368,"classification":369,"enforcement":370,"event":371,"event_backfill":372,"pma":373,"warning_letter":374},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]